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Chapter 1
GENERAL INTRODUCTION
Clinical reasoning and decision making are important aspects in daily clinical practice of 
physicians. They need to detect and treat conditions threatening the health of a patient, 
while doing no further harm. Moreover, this evaluation often needs to take place in a short 
time frame, especially in hospitalized patients and those presenting at the emergency 
department with fever and acute symptoms. Clinical assessment starts with history 
taking and physical examination. This results in a differential diagnosis guiding the initial 
investigations and treatment. Fever is a sign of inflammation and can be due to both a 
variety of infectious diseases and several non-infectious inflammatory disorders, such as 
autoinflammatory conditions, autoimmune disorders, allergy and cancer. Although certain 
symptoms and signs give clues to the origin of the inflammation, for example the presence 
of myalgia in influenza [1] and chills in bacteremia [2], their discriminative capacity alone is 
usually insufficient [3]. Atypical presentation of diseases and unfamiliarity of the physician 
with certain diseases can further decrease the value of the history and physical examination 
as solitary diagnostic tool for inflammatory disorders [4, 5]. As a consequence, the initial 
therapy is often needlessly broad and may be ineffective. 
Patient outcome depends on timely administration of effective antimicrobial therapy in 
bacterial or fungal infection [6, 7]. However, most microbiological tests such as culture, 
serology and molecular methods can only partially help during this window of opportunity 
given their limitations: difficulty to obtain a relevant biological specimen, low sensitivity, high 
costs and long turnaround times. Therefore, additional rapidly available diagnostic markers 
are urgently needed to differentiate between these diseases. Two groups of biomarkers 
are used in this context. First, biomarkers derived from pathogens (microbial components). 
Some of these have found their way into daily clinical practice: Legionella and pneumococcal 
urinary antigen tests in pneumonia [8, 9] and the demonstration of circulating fungal cell 
wall components for suspected invasive fungal infections [10]. Unfortunately, however, for 
most infectious diseases, these biomarkers are not available. Based on the concept that 
different pathogens elicit distinct early immune responses, a promising second group of 
rapidly available diagnostic tests could consist of biomarkers that reflect the host immune 
response.
A pathogen-specific immunological reaction also forms the basis of serology, one of the 
traditional microbiological tests. However, the antibody response can be delayed and 
the interpretation usually relies on the kinetics of this response, thereby often providing 
etiological information only retrospectively. Already a century ago the principle of the 
immune response as diagnostic modality was recognized. Türk described the atypical 
lymphocyte, a non-malignant leukocyte of lymphoid origin, present in small numbers in 
the peripheral blood of healthy subjects [11]. Subsequently, the presence of a marked 
atypical lymphocytosis was linked to the clinical features of infectious mononucleosis. 
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This immunological phenomenon has its value to the treating physician because of its high 
specificity for (serologically confirmed) primary Epstein-Barr virus infection in the context of 
a (young) patient with fever, tonsillar pharyngitis, and lymphadenopathy [12, 13]. Nowadays, 
besides leukocyte count and leukocyte differential, C-reactive protein (CRP) and procalcitonin 
(PCT) have gained a prominent place in the initial approach to the febrile patient. PCT has 
proved its usefulness in guiding treatment of lower respiratory tract infections (LRTI) in the 
emergency room, while the use of C-reactive protein has been shown to reduce antibiotic 
prescribing for LRTI by general practitioners [14]. Besides these markers, different groups 
of potential biomarkers at different levels for obtaining a specific signature of inflammatory 
conditions can be derived from the immune system (Figure 1). 
Different clinical scenarios require different kinds of biomarkers. Although the likelihood of an 
infectious cause of inflammation is higher than a non-infectious cause in acute inflammatory 
episodes, flares of autoimmune or autoinflammatory disorders and cancer are important 
diagnostic considerations at the emergency department. Similarly, fever in hospitalized 
patients may, besides infections, as well be caused by drug-induced allergies, thrombosis or 
phlebitis. For these distinctions a ‘pan-infectious’ biomarker is necessary, while a biomarker 
differentiating between certain classes of microorganisms will be helpful in the treatment 
Figure 1. Potential groups of inflammatory diagnostic biomarkers. Besides shifts in leukocyte subsets, different 
cellular and soluble markers may aid in the diagnostic work-up of inflammatory disorders. Gene expression profiling 
of circulating leukocytes combines multiple changes induced by the inflicting agent. In addition to chemokines 
and cytokines and acute-phase proteins, other proteins involved in the immune response, such as procalcitonin, 
neopterin and antiviral enzymes are potential candidates for diagnostic biomarkers. The expression of different 
receptors, including pattern-recognition receptors, is changed during inflammatory episodes and several receptors 
have soluble counterparts released during inflammation.
12
Chapter 1
of LRTI (viral versus bacterial infection) or sepsis in neutropenic patients (bacterial versus 
fungal infection). The ultimate challenge will be to discriminate between different pathogens 
in a certain class. For example, the prediction of Legionella, other atypical bacteria or for 
instance influenza as cause of pneumonia can guide initial antimicrobial prescription. One 
could also think of fever and rash or fever in the returning traveler as a well-defined clinical 
scenario suited for specific prediction (or exclusion: malaria) of a particular infectious cause.
Immunodeficiencies are major predisposing factors to infectious diseases. Contrary to the 
traditional view of primary immunodeficiencies as rare monogenetic disorders, recent 
evidence suggests that even individuals suffering from a single unusual infection could 
be affected by an immune defect [15, 16] and thus, a primary immunodeficiency (PID) 
should be considered in many patients. Unraveling the pathogenesis and the establishment 
of reliable markers of these immune defects are essential to improve the care for these 
patients. Pattern recognition is the key to identification of a PID, since the diagnostic work-
up has a phenotypic approach [17, 18]. Both tests assessing the structure and the function 
of the immune system are part of the diagnostic protocols, but little is known about the use 
of functional assays testing the integrity of cytokine production in stimulated peripheral-
blood mononuclear cells in this context. However, the functional characterization of the 
immune deficit has the potential to reveal underlying genetic defects and early recognition 
of a PID facilitates preventative or therapeutic strategies, including supplementing deficient 
pro-inflammatory cytokine production [19-21]. 
OUTLINE OF THE THESIS
The general aim of this thesis is to investigate novel diagnostic strategies based on host 
immune responses for the early diagnosis of infections and inflammatory diseases, and for 
establishing the presence of immunodeficiencies.
Compared to bacterial infections, viral infections often do not or to a lower extent induce 
proinflammatory cytokines and acute-phase proteins. Chapter 2 will investigate the early 
inflammatory response among children with measles in a prospective study. Besides 
increasing our understanding of measles-induced inflammation, we speculate on the value 
of this viral signature in the differential diagnosis of infectious diseases. The use of a panel 
of host defense-related biomarkers is further assessed in Chapter 3. In septic patients 
presenting at the emergency department with symptoms and signs of a lower respiratory 
tract infection, the additional value of PCT, interleukin (IL)-6, IL-18 or soluble triggering 
receptor expressed on myeloid cells-1 (sTREM-1) to CRP will be studied.
Toll-like receptors are germ-line encoded receptors belonging to the pattern recognition 
receptors (PRR). By recognizing pathogen-associated molecular patterns (PAMPs), they 
orchestrate the innate and adaptive immune responses to eliminate the specific pathogen. 
1Chapter 1
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Recently, soluble forms of TLR2 and 4 have been described [22, 23]. In Chapter 4 we 
will investigate the in-vitro release of sTLR2 and sTLR4 and the kinetics during human 
experimental endotoxemia. Furthermore, since different pathogens stimulate different PRRs 
[24], we hypothesize that sTLR2 and sTLR4 are differentially released during miscellaneous 
inflammatory diseases and can therefore serve as diagnostic biomarkers. Galectin-3, a 
member of the β-galactoside-binding galectin family, functions as a PRR of the cell wall 
of Candida albicans [25]. Chapter 5 will focus on the potential of circulating galectin-3 to 
discriminate between infection and non-infectious inflammation and, given its importance 
in antifungal host defense, on the discrimination between fungal and bacterial infections.
Another strategy in rapid diagnosis, with the additional advantage of being noninvasive, 
is breath analysis. Prototypic examples, well known from daily clinical medicine, are the 
acetone smell and the fetor hepaticus in diabetic ketoacidosis and hepatic encephalopathy, 
respectively. Since the description of nitric oxide (NO) in exhaled breath, most research 
on exhaled NO has focused on inflammatory diseases, particularly asthma [26], but, data 
on pneumonia are scarce. In Chapter 6 we will investigate the difference in exhaled NO 
between intubated patients with sepsis with or without pneumonia and non-infectious 
controls. We will also investigate whether the primary source of exhaled NO is the infected 
lung or whether the exhaled NO reflects pulmonary clearance of systemically produced NO.
Until now, cytokine production assays have predominantly been used in the search for novel 
immunodeficiencies [21]. However, data on the value of cytokine production in patients 
with infectious or autoinflammatory diseases are not available. Therefore, in Chapter 7, 
we will assess the value of cytokine production assays in patients suffering from either a 
recurrent infection, an unusually severe course of an infection, or from a autoinflammatory 
disorder. 
Chapter 8 contains a review of the clinical use of diagnostic inflammatory biomarkers in 
differentiating inflammatory disorders and is followed by a summary of the new findings 
and conclusions in Chapter 9.
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ABSTRACT
Among 167 hospitalized children with measles, circulating concentrations of interleukin (IL)-
6, IL-1β, IL-1Ra, IL-4, interferon (IFN)-α, IFN-β, and Thelper17 cytokines were low, whereas 
leukopenia, increased lactate dehydrogenase, IL-18, and IFN-γ concentrations characterized 
the inflammatory response. Besides understanding measles-induced immunologic 
responses, this profile may assist in differential diagnosis. 
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INTRODUCTION
The inflammatory response induced by measles virus (MV) infection has been of substantial 
interest, particularly because of the generalized immune suppression that follows the 
effective virus-specific immune response [1, 2]. While many bacterial infections are 
accompanied by a significant rise in pro-inflammatory cytokines and plasma acute-phase 
proteins such as C-reactive protein (CRP), viral infections often lack these characteristic 
changes. This impairs the capacity to diagnose rapidly an acute viral infection such as 
measles. In recent years the novel cytokine IL-18 has been found to be strikingly elevated 
during many viral infections [3]. Characterization of acute inflammatory response patterns 
not only increases our understanding of immunologic responses during acute measles, but 
may also lead to the description of a pathogen-specific inflammatory profile, which may 
provide a useful tool for diagnosis [4, 5]. Therefore, we aimed to characterize the acute 
inflammatory response in measles during a large outbreak among unvaccinated Roma 
(Gipsy) children in the Cluj county, Romania.
PATIENTS AND METHODS
Study design and patients
After approval of the Medical Ethics Committee and with parental consent, we performed 
this prospective study among hospitalized measles patients at the Pediatric Department of 
the Clinical Hospital of Infectious Diseases Cluj-Napoca, Romania between May 2011 and 
July 2011. The clinical diagnosis of measles was confirmed by the demonstration of IgM 
antibodies against MV. 
Thirty-four healthy children (median age 5 years, 42% male) and 28 children with another 
exanthematous febrile illness, seronegative for IgM against MV, and admitted in the same 
time period, served as control groups. One had varicella infection, and eight children had 
been exposed to rubella patients. 
Measurement of inflammatory markers
Upon admission, and from 27 patients 5 days later, inflammatory mediators were measured 
in serum. Interleukin (IL)-1β, IL-1Ra, IL-6, IL-18 Luminex assays (Merck Millipore, Billerica, 
MA) had a lower detection limit of 2.4 pg/mL, 9.8 pg/mL, 2.4 pg/mL, 2.4 pg/mL, respectively. 
IL-4 (R&D systems, Minneapolis, MN), Interferon (IFN)-α, IFN-β (PBL Interferon source, 
Piscataway, NJ), and IFN-γ (Sanquin, Amsterdam, the Netherlands) ELISAs had a lower 
detection limit of 10 pg/mL, 12.5 pg/mL, 20 pg/mL and 7.8 pg/mL, respectively. IL-12p70, 
IL-23, IL-22, IL-17A and IL-17F (Luminex, Merck Millipore, Billerica, MA), were measured in 
a subgroup of 39 patients and 7 healthy controls, with a sensitivity of 3.3 pg/mL, 35.5 pg/
mL, 16.8 pg/mL, 35.6 pg/mL, and 6.8 pg/mL, respectively. Results of leukocytes, CRP, lactate 
dehydrogenase (LDH), alanine transferase (ALT) and aspartate aminotransferase (AST) were 
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retrieved from the electronic laboratory reporting system and had the following reference 
values: CRP <3 mg/L, LDH 240-480 U/L, ALT <40 U/L and AST <37 U/L. Patients were grouped 
into three groups (low, normal or high) according to age-specific leukocyte values. 
Statistical analysis
Where appropriate, the Mann-Witney U test, the Kruskal-Wallis test with Dunn’s post test, 
the Chi-square (or Fisher’s exact) test or Wilcoxon signed rank test was used to compare 
medians or proportions. To assess correlations between parameters Spearman correlation 
coefficients were calculated. To develop a prediction model for the presence of thrush, we 
used logistic multivariate regression analysis (forced entry method). We used SPSS 20.0 
(IBM, Armonk, NY) and Graphpad Prism (GraphPad Software, La Jolla, CA) to analyze the 
data. 
RESULTS
Clinical characteristics
A more detailed description is shown in Table 1. Briefly, the median age of affected measles 
children was 4 years (interquartile range [IQR] 1-6), 42% was male and they presented 
after a median of 2 days after the onset of rash (IQR 1-3) compared to 6 years (IQR 1-16; 
P=0.04), 39% (P=0.80) and 2 days (IQR 2-3; P=0.005) in the control group, respectively. None 
received supplemental vitamin A. Radiographically-confirmed pneumonia was present in 
65% of the patients, four of which were admitted to the ICU for non-invasive ventilation. 
Encephalitis and mortality were absent. Oral candidiasis (clinical suspicion was confirmed 
by culture) tended to be more prevalent among the measles infected children than in the 
infectious control group: 43% versus 25%, P=0.07. Multivariate analysis (both infectious 
groups combined) showed measles infection and low age (≤ 1yr, lowest quartile) to be 
independent predictors of oral candidiasis: OR 2.71 (95% CI 1.04-7.02, P=0.04) and OR 2.81 
(95% CI 1.40-5.61, P=0.006), respectively, while lymphopenia, sex, antibiotic use or any of 
the inflammatory markers were not.
Inflammatory response and biochemical data
Figure 1 summarizes the inflammatory response. Thirty-six percent of the measles patients 
had leukopenia, predominantly caused by lymphopenia, compared to 14% in the infectious 
control group (P=0.02). CRP, IL-6, IL-1β, IL-1Ra, IL-4, IFN-α and IFN-β concentrations were 
low (Figure 1), whereas IL-18 and IFN-γ concentrations were significantly higher in measles 
patients. There was no correlation between IL-18 and IFN-γ concentrations (rs = 0.13, P=0.11). 
Only IL-18 concentrations changed in time: it decreased from 349 pg/mL (IQR 202-615) to 
218 pg/mL (IQR 163-394), P=0.04. Sepsis or pneumonia did not influence cytokine response, 
except for IFN-γ, which was higher in the patients with sepsis compared to patients without 
sepsis or severe sepsis (39 pg/mL [IQR 22-66], versus 26 pg/mL [IQR 11-51] and 21 pg/mL 
[IQR 18-37], P<0.05). Ninety-four percent and 27% of measles patients compared to 22% and
2Chapter 2
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Table 1. Clinical characteristics, symptoms and complications. 
Variable Measles
(n=167)
Other
(n=28)
P-value
Sex, n (% male) 70 (42) 11 (39) P=0.80
Age, yrs [median (IQR)] 4 (1-6) 6 (1-16) P=0.04
Interval between onset rash and admission, days [median 
(IQR)] 2 (1-3)
2 (2-3) P=0.005
Coryza, n (%) 167 (100) 20 (71) P<0.001
Cough, n (%) 167 (100) 20 (71) P<0.001
Temperature, ºC [median (IQR)] 38.8 (38.2-39.0) 38 (37.9-38.5) P<0.001
Oxygen saturation, % [median (IQR)] 96 (95-97) 98 (98-99) P<0.001
Severitya P<0.001
   No sepsis, n (%) 36 (22) 23 (82) -
   Sepsis, n (%) 119 (71)  5 (18) -
   Severe sepsis, n, (%) 12 (7) 0 (0) -
   Septic shock, n, (%) 0 (0) 0 (0) -
Length of hospital stay, days [median (IQR)] 5 (4-6) 4 (2-5) P=0.003
Patients admitted to ICU, n (%) 4 (2) 0 (0) P=1.0
In-hospital mortality rate, n (%) 0 (0) 0 (0) -
Encephalitis, n (%) 0 (0) 0 (0) -
Pneumonia, n (%) 108 (65) 2 (7) P<0.001
   Need for supplemental oxygen, n (% patients with     
   pneumonia)
40 (37) 0 (0) -
   Interstitial, n (% of pneumonia) 66 (61) 2 (100) -
   Alveolar infiltrate, n (% of pneumonia) 6 (6) 0 (0) -
   Mixed, n (% of pneumonia) 36 (33) 0 (0) -
Bronchitis, n (%) 23 (14) 0 (0) P=0.04
Bacterial pharyngitis, n (%) 16 (10) 4 (14) P=0.13
Thrush, n (%) 72 (43) 7 (25) P=0.07
Diarrhea, n (%) 18 (11) 6 (21) P=0.24
Dehydrationb, n (%) 101 (60) 6 (21) P<0.001
   Grade 1 (1-2) 1 (1-2) -
Abbreviations: IQR, interquartile range, n, number.
aAccording to the international definitions described in Goldstein B et al. Pediatr Crit Care Med 2005;6:2-8.
bAccording to the guideline of the British Columbia Medical Association, published online (www.bcguidelines.ca; 
accessed at 13 August 2013).
11% of the diseased control group had elevated concentrations of LDH (P<0.0001) and ALT 
or AST (P=0.07), respectively. IL-12p70, IL-23, IL-22, IL-17A and IL-17F concentrations were 
compared between 19 with and 20 measles patients without thrush and 7 healthy controls, 
and were undetectable in almost all patients, and did not differ between the groups. 
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Figure 1. Plasma concentrations upon admission of IL-6, IL-1β, IL-1Ra, IL-18, IFN-γ, IL-4, IFN-α and IFN-β in patients 
with measles (A), other febrile illness with rash (B), and healthy children (C). P-values were calculated with the 
Kruskal-Wallis test (comparison between the three groups, arrow) followed by Dunn’s post Kruskal-Wallis test 
(comparison between two groups, bars). Concentrations of CRP, LDH and leukocyte and lymphocyte counts are 
shown for patients with measles (A) and other febrile illness with rash (B), with reference values indicated by the 
grey areas. The reference values of leukocyte and lymphocyte counts are age-dependent and range from 4.5-10 and 
1-4 *10^9/L (> 13 years, dashed lines) to 6-18 and 2-10.5 *10^9/L (<4 years, solid lines), respectively. Comparisons 
were made by the Mann-Whitney U test and are shown by bars. Median concentrations are numerically displayed 
for the different groups. N.s. denotes not significant.
2Chapter 2
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DISCUSSION
By systematically analyzing known inflammatory mediators in a clinically well-defined 
measles cohort, we show that the acute inflammatory reaction in measles is characterized 
by lymphopenia and elevated concentrations of IL-18 and IFN-γ, in the context of low 
circulating concentrations of IL-6, IL-1β, IL-1Ra, IL-4, type I IFNs and Th17-derived cytokines.
The rash marks the onset of viral clearance by MV-specific CD8+ T-cells [6] and is accompanied 
by a rise in IFN-γ [2, 7]. The increased IL-18 concentrations also illustrate this T-helper-1 
(Th1) response and we confirm this pattern of immune activation in a genetically and 
environmentally different population [8]. IL-18 release from monocytes and macrophages 
is regulated, similarly to IL-1β, both at transcriptional level and at the inflammasome which 
cleaves pro-IL-1β and pro-IL-18 into the biologically active forms. IL-18 release suggests 
activation of the inflammasome in measles, which is supported by the finding of increased 
Nlrp3 transcripts in peripheral blood mononuclear cells [9]. Although the IL-1β gene is 
up-regulated and IL-1β concentrations are slightly higher compared to controls [9], IL-18 
release is dominant in measles, as explained by the differential gene expression, synthesis 
and secretion of both cytokines [10].
The convalescence phase is dominated by a Th2 response, as illustrated by moderately 
elevated plasma concentrations of IL-4 and IL-13 in some patients, potentially explaining 
MV-induced immunosuppression [2]. Additionally, lymphopenia (caused by apoptosis 
and responsible for LDH release), lymphocyte unresponsiveness and defective 
lymphoproliferation contributes to the MV-induced cellular immune depression [1, 6]. 
The latter probably explains why measles infection was an independent risk factor for oral 
thrush, particularly in young infants. Circulating levels of Th17 cytokines did not explain the 
different susceptibility to thrush, although this does not rule out  differences in mucosal 
Th17 responses that may be diagnosed upon ex-vivo stimulation. 
During incubation time, before the adaptive immune system is fully activated, epithelial 
cells, dendritic cells, and alveolar macrophages in the respiratory tract are the prime targets 
of MV[6]. Through ligation of pattern recognition receptors, retinoic acid inducible gene-I 
(RIG-I) and Toll-like receptor (TLR)3, an important first-line antiviral defense is induced: type 
I IFNs (IFN-α and IFN-β) [11, 12] . However, this appears to be an early and cell-specific 
effect, since mRNA of IFN-stimulated genes in peripheral blood mononuclear cells at the 
time of the rash was not increased [9]. Therefore, the moment of sampling potentially 
explains the low IFN-α and IFN-β signal in our study. Additionally, given the paracrine and 
autocrine effects of type I IFNs, circulating concentrations may not represent IFN induction 
at tissue level.
The absence of classical features of the acute-phase response, as leukocytosis, elevated 
concentrations of CRP, IL-6 and IL-Ra, in combination with elevated IFN-γ and IL-18 
24
Chapter 2
concentrations, as demonstrated here, represents a viral signature [3] and we suggest 
cytokine activation and biomarker patterns may provide a valuable tool in differential 
diagnosis. Interestingly, our infectious control group, probably of viral origin, displayed lower 
IFN-γ and IL-18 responses compared to measles patients, suggesting the acute inflammatory 
profile may not only be helpful to discriminate between classes of microorganisms, but also 
between different pathogens within a certain class [5]. Future studies are warranted to test 
this hypothesis. Furthermore, while a previous study on IL-18 reported only group means 
[8], we show individual values, which illustrates individual patients not necessarily follow 
the group pattern. 
The current study also has some limitations. Firstly, in most of the infectious control patients 
the causative agent was unknown. However, rubella was prevalent and a likely cause. 
Secondly, repeated measurements would have offered the opportunity to describe the 
immunological changes more precisely. Thirdly, differences between groups may have been 
present at levels below the sensitivity of the assays. Finally, we described the response in 
hospitalized patients only and this may be different, at least at the level of the extent of the 
changes, from an outpatient population. 
The present study clearly shows the burden of a measles outbreak as consequence of low 
vaccine coverage among certain groups. We demonstrated the acute inflammatory response 
of measles to be different from the classical acute phase response and to be characterized 
by leukopenia and increased concentrations of IL-18 and IFN-γ.
2Chapter 2
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ABSTRACT
Background: To investigate whether additional determinations of plasma lipopolysaccharide 
binding protein (LBP), procalcitonin (PCT), interleukin (IL)-6, IL-18, or soluble triggering 
receptor expressed on myeloid cells-1 (sTREM-1) to C-reactive protein (CRP) improve the 
discrimination between bacterial and viral lower respiratory tract infections (LRTI).
Methods: Out of 342 patients visiting the emergency department because of a suspected 
infection and  ≥ 2 clinical signs of sepsis, 56 patients with proven bacterial (n=39) or viral 
(n=17) LRTI were included. The area under the ROC curves (AUROC) of the five possible 
combinations of CRP with one other biomarker were compared with the AUROC of CRP alone. 
Next, the same analysis was performed in the group of patients with a CRP concentration 
with < 95% specificity for bacterial LRTI.
Results: While CRP, PCT, IL-6, sTREM-1, and LBP concentrations were significantly different 
between patients with bacterial or viral LRTI, the AUROC of CRP (0.82, 95%CI 0.70–0.93) did 
not increase after combination analyses. After exclusion of patients with a CRP >150 mg/L, 
biomarker panel analyses did not improve diagnostic accuracy of CRP either. 
Conclusions: Combining CRP with LBP, PCT, IL-6, IL-18, or sTREM-1 does not improve 
differentiation between patients with a bacterial or viral LRTI compared with CRP alone.
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INTRODUCTION
Morbidity and mortality associated with lower respiratory tract infections (LRTI) remains 
significant, despite improved diagnostic and therapeutic treatment strategies in recent 
years [1]. The early initiation of antibiotic therapy has a major impact on the clinical 
outcome of critically ill patients [2, 3]. Several laboratory diagnostic tests are currently used 
for establishing an etiologic diagnosis. However, difficulty in obtaining relevant specimens, 
the low sensitivity or specificity of the used tests, high costs, and the absence of test results 
within the critical window for initiating adequate treatment, often result in prescription 
of antibiotic therapy in the absence of a bacterial infection. This may have potentially 
deleterious consequences such as anaphylactic reactions, antibiotic resistance, and high 
costs [4]. Rapid tests that provide additional insight in the bacterial/viral etiology of infection 
may guide appropriate use of antibiotics and are urgently needed. 
Both C-reactive protein (CRP) and procalcitonin (PCT) concentrations have been used to 
initiate and monitor the antibiotic use for LRTI [5, 6]. However, the specificity of single 
biomarkers in terms of etiologic distinction between bacterial and viral inflammatory insults 
remains cumbersome [7, 8], and a combination of markers could prove more reliable. The 
usefulness of IL-18 as a viral marker is supported by the reported high concentrations in HIV, 
dengue hemorrhagic fever, EBV, and CMV infections [9-12]. Triggering receptor expressed 
on myeloid cells-1 (TREM-1) is expressed on neutrophils and monocytes upon exposure to 
bacteria and fungi. Soluble TREM-1 (sTREM-1) has been proposed to be of diagnostic value 
in bacterial infections [13]. Lipopolysaccharide (LPS)-binding protein (LBP) is an acute phase 
protein produced by hepatocytes that binds LPS to form a LPS-LBP complex during bacterial 
infections [14]. In children, LBP has excellent sensitivity for diagnosing invasive bacterial 
infections [15]. Interleukin (IL)-6 is the chief stimulator of the production of most acute-
phase proteins, such as CRP and LBP. Thus, IL-6 is a potential marker for the early phase of 
infection.
It is suggested that determination of several biomarkers, or a panel of biomarkers, may 
improve their predictive value [16-20], but clinical evidence for this notion is scarce [16-20]. 
Also, differences in the plasma concentrations between, e.g., viral and bacterial infection 
groups are frequently reported, while the discriminating power for the individual patient 
remains unclear. Therefore, in the present study we assessed whether combination of the 
most commonly used biomarker CRP with LBP, PCT, IL-6, IL-18, or sTREM-1 can improve the 
discriminating ability in patients with a proven bacterial or viral LRTI.
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PATIENTS AND METHODS
Study design
This study was a prospective single center study, performed at the emergency department 
(ED) of a 953-bed university hospital in the Netherlands between November 2006 and 
May 2007. During the study, medical policy at the ED and the nursing wards was based 
on the standard basic clinical chemistry test results, in combination with a physical and 
additional examination depending on the clinical suspicion, and not on the results of the 
novel inflammatory markers described in this manuscript. Prior to the conduct of this study, 
the local Medical Ethics Committee was informed. Although they waived the need for a 
written informed consent, patients were informed about the study and the acquisition of 
supplementary plasma. 
Study population
The study inclusion criteria were: 
(1) patients (≥16 years old) visiting the ED because of a suspected infection, who had at 
least two of the following clinical signs of sepsis: temperature >38.3°C or <36°C, heart rate 
>90/min, respiratory rate >20/min, chills, altered mental status, systolic blood pressure <90 
mmHg, mean arterial pressure <65 mmHg, hyperglycaemia (plasma glucose >6.8 mmol/L) in 
the absence of diabetes mellitus [21].
(2) signs of a LRTI: fever, cough with or without sputum, chest pain, dyspnoea, and altered 
breath sounds on auscultation and/or the presence of an infiltrate on chest X-ray. 
(3) patients with a microbiologically confirmed bacterial or viral infection. Since the primary 
goal of this study was not to differentiate between patients with or without infection, but 
to establish the value of biomarkers in discriminating between bacterial and viral LRTI, we 
deliberately selected only patients with a microbiologically confirmed bacterial or viral 
infection. 
All patients not fulfilling these inclusion criteria were excluded. 
Data collection
Cultures from sputum and blood, PCR on nose and throat swabs, antigen tests and serology 
were used to establish a diagnosis. Blood samples were taken for basic clinical chemistry 
tests and the measurements of the inflammatory mediators. Two blood cultures for 
microbiological testing were performed. Only CRP results were known to the attending 
physician. Blood was collected into two 3 mL lithium-heparin coated tubes for PCT, IL-6, LBP, 
sTREM-1, IL-18, and for basic clinical chemistry tests including CRP. Plasma was obtained 
by centrifugation of the blood at 4°C with 2000 rpm for 15 minutes after which the plasma 
was frozen at -80°C until measurements took place. CRP was measured by use of the Abbott 
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Aeroset (Abbott Diagnostics, Chicago, IL) with a lower detection limit of 5 mg/L. PCT was 
measured by use of the Kryptor PCT (Brahms, Hennigsdorf, Germany) with a detection limit 
of 0.02 µg/L. IL-6 and LBP were measured by use of the Immulite 2500® (Siemens, Breda, The 
Netherlands) with a lower detection limit of 2 pg/mL and 1.2 µg/mL, respectively. Circulating 
IL-18 levels were measured using a commercial Luminex assay (BioRad, Hercules, CA) with a 
lower detection limit of 15 pg/mL. Circulating sTREM-1 was assessed by a commercial ELISA 
kit (R&D Systems, Minneapolis, MN), according to the instructions of the manufacturer with 
a lower detection limit of 62.5 pg/mL.
Statistical analysis
Data are expressed as medians with interquartile range. The Mann-Whitney U test was 
used to determine the difference of each marker between the two groups of patients. ROC 
curve statistics were applied for each single marker. Logistic regression analysis was used to 
estimate the predicted probabilities for CRP alone and in a model with CRP in combination 
with one of the other five biomarkers. These data were used for the generation of ROC 
curves. The area under the ROC curves (AUROC) of the five possible combinations of CRP 
with one other biomarker was compared with the AUROC of CRP alone. The method 
described by Hanley and McNeil was used for comparing the AUROC [22]. As very high 
CRP values are highly specific for bacterial infections [23] and no additional biomarkers are 
needed, we additionally analyzed the combination of markers in the subgroup of patients 
with a moderately increased CRP that may benefit the most from panel analysis. Therefore, 
the cutoff value of CRP leading to a specificity >95% for a bacterial LRTI (at the top end 
of CRP values) was determined. Next, a ROC curve of CRP with one other biomarker was 
constructed in a similar way as described above for the subgroup of patients with a CRP 
below this cutoff value. All tests were two-sided, and P<0.05 was considered statistically 
significant. Data were analyzed using SPSS version 18.0 (IBM, Armonk, NY) and MedCalc 
version 11.3.1.0 (MedCalc Software, Mariakerke, Belgium).
RESULTS
A total of 342 patients with a suspected infection and ≥ two clinical signs of sepsis were 
admitted to the ED. Of these patients, 123 had a pulmonary focus for infection of whom 
58 had a microbiologically confirmed LRTI. Two patients were excluded because of a fungal 
infection (Pneumocystis jirovecii). We included 39 patients with a bacterial LRTI and 17 
patients with a viral LRTI for further analysis. No patients with both a bacterial and a viral 
infection were diagnosed. With the number of patients included, this study has 80% power 
to pick up an increase of the AUROC of 10% in the whole group and an increase of the 
AUROC of 20% in the subgroup of patients with a CRP concentration <150 mg/L. 
The demographic and clinical parameters of the two groups are shown in Table 1. Table 2 
shows the microbiological data. CRP, IL-6, LBP, PCT, and sTREM-1 were significantly higher in 
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Table 1. Patient characteristics.
Variable Bacterial infection
(n = 39)
Viral infection
(n = 17)
Patient characteristics 
   Sex, % male 69 47
   Age, yrs [median (IQR)] 60 (50-70) 54 (32-63)
   Number of SIRS criteria [median (IQR)] 2 (2-3) 2 (2-3)
   Patients admitted to nursing ward or ICU [n (%)] 35 (90%)  16 (94%)
   Length of hospital stay, days [median (IQR)] 8 (5-20) 7 (3-18)
   In-hospital mortality rate [n (%)] 2 (5%) 0 (0%)
   Bacteraemia [n (%)] 11 (28%) 0 (0%)
 
Table 2. Isolated microorganisms.
Bacterial infection (n = 39) Viral infection (n = 17)
Streptococcus pneumoniae 10 Influenza A 5
Coxiella burnetii 9 Influenza B 4
Haemophilus influenzae 6 Respiratory syncytial virus 1
Mycoplasma pneumoniae 3 Metapneumovirus 1
Pseudomonas aeruginosa 3 Parainfluenza virus 3
Staphylococcus aureus 1 Influenza A +  respiratory syncytial virus 2
Legionella pneumophila 1 Picornavirus + rhinovirus 1
Citrobacter freundii 1
Corynebacterium propinquum 1
Escherichia coli 1
Streptococcus pneumoniae + Moraxella catarrhalis 1
Haemophilus influenzae + Pseudomonas aeruginosa 1
Staphylococcus aureus + Streptococcus pneumoniae 1
the bacterial group compared with the viral group. IL-18 did not differ between the bacterial 
and the viral group (Figure 1).  
CRP had an AUROC of 0.82 (95% CI 0.70–0.93). The other biomarkers did not have a larger 
AUROC. The combination of CRP with any of the other makers had no significant effect on 
the AUROC compared to CRP alone (Table 3).
For CRP, a level of >150 mg/L was highly specific for a bacterial infection (95% CI 0.80–
1.0). However, only 49% (n=19) (95% CI 0.32–0.65) of the patients with a bacterial LRTI had 
concentrations >150 mg/l. In the lower range, considerable overlap of CRP concentrations 
existed between patients with viral (n=17) and bacterial infections (n=20), which had a 
negative impact on the specificity of the test and impeded the generation of a cutoff value 
with an acceptable specificity for viral LRTI. Apart from the patients with bacterial infection 
and a CRP >150 mg/L (highly specific for bacterial LRTI), the combination of the CRP value 
with any one of the other biomarkers in the remaining patients with a  CRP <150 mg/L 
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Table 3. Area under the ROC curve (AUROC) for diagnosing bacterial lower respiratory tract infection of CRP and 
CRP in combination with other markers (n=56).
Marker AUROC (95% CI) P-valuea
CRP 0.82 (0.70–0.93)
CRP + LBP 0.85 (0.74–0.95) 0.7
CRP + IL-6 0.84 (0.74–0.95) 0.8
CRP + PCT 0.84 (0.73–0.95) 0.7
CRP + sTREM-1 0.83 (0.72–0.94) 0.9
CRP + IL-18 0.82 (0.70–0.93) 0.6
a P-value for the comparison with the AUROC of CRP.
Table 4. Area under the ROC curve (AUROC) for diagnosing bacterial lower respiratory tract infection of CRP and 
CRP in combination with other markers in patients with a CRP < 150 mg/L (n=37). 
Marker AUROC (95% CI) P-valuea
CRP 0.64 (0.45–0.84)
CRP + LBP 0.68 (0.50–0.86) 0.9
CRP + IL-6 0.70 (0.53–0.88) 0.8
CRP + PCT 0.69 (0.50–0.88) 0.7
CRP + sTREM-1 0.64 (0.46–0.83) 1.0
CRP + IL-18 0.62 (0.43–0.81) 0.7
Abbreviations: CI, confidence interval.
aP-value for the comparison with the AUROC of CRP.
Figure 1. Plasma concentrations of CRP, IL-6, LBP, PCT, sTREM-1, and IL-18 in patients with viral lower respiratory 
tract infection (LRTI) compared with LRTI of bacterial origin (n=56). Horizontal bars represent medians of the 
concentrations; the median is reported above the scatter plots in the different figures.
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(n=37) did not increase the AUC to discriminate between a viral and bacterial LRTI in this 
subgroup of patients (Table 4).
DISCUSSION
The main finding of the present study is that while several inflammatory markers are 
significantly different between a group of bacterial and viral LRTI patients, addition of these 
markers to CRP was not superior to CRP alone in discriminating between bacterial and 
viral LRTI in septic patients. CRP as a single biomarker is a useful parameter to suggest the 
bacterial etiology of an infection, since a concentration >150 mg/L is highly specific for a 
bacterial infection. However, lower concentrations of CRP are often observed during both 
viral and bacterial infections. Unfortunately, biomarker panel analyses in this subgroup of 
patients did not improve diagnostic accuracy of CRP either and are therefore not suitable to 
guide therapy for the individual patient. 
Antibiotics are the cornerstone in the treatment of bacterial infections and early antibiotic 
administration has been a crucial part of the surviving sepsis campaign [24]. On the other 
hand, a dramatic increase in antibiotic resistance has emerged without the prospect of 
development of novel classes of antimicrobial agents [4, 25]. Therefore, reduction of the 
unnecessary use of antibiotics is mandatory. 
Unfortunately, symptoms and signs routinely used in the diagnosis of LRTI have limited value 
in predicting the requirement of antibiotic therapy [23]. As a consequence, a multitude of 
biomarkers gained a lot of attention in differentiating bacterial from viral infections and 
in prognostication. Among these, CRP and PCT have found their way into daily practice 
[5, 6]. LRTI caused by various classes of microorganisms are characterized by different 
concentrations of PCT and CRP [16, 23, 26, 27]. However, the high a priori chance of having a 
bacterial infection [28, 29], together with the considerable overlap between the biomarkers 
in the lower range, complicates the exclusion of a bacterial cause of an infection by the use 
of individual biomarkers [16, 23, 29].
To overcome the problem with single marker analysis, some studies advocated panel analysis 
[16-19, 29, 30]. While some promising results have been reported [17, 18], studies including 
only patients with LRTI found no relevant effects of combining markers on diagnostic 
accuracy [16, 19, 29, 30]. We used the addition of a second biomarker to CRP to examine the 
discriminatory power of laboratory testing, both in the group as a whole and in a subgroup 
of patients with relatively moderately increased CRP levels that potentially would benefit 
most from this approach. In contrast with most previous studies, we included both proven 
bacterial and viral markers aimed at increasing the discriminative power. For example, IL-18 
is a cytokine playing an important role in antiviral immunity [9-12], and was expected to be 
a sensitive marker for diagnosing viral infections, while other markers are mechanistically 
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related to the immune response against bacterial infections. 
Most biomarkers examined in previous studies are stimulated both by bacterial and viral 
pathogens, but reach higher values during bacterial invasion. Therefore, moderately 
increased concentrations of these biomarkers can be found in both categories. Combination 
of these bacterial markers may only be beneficial if they do not correlate well with each 
other. Furthermore,  a potentially suitable biomarker for combination analysis in future 
studies should demonstrate increased levels during viral infections. Bystanders of viral 
replication or proteins released upon virus recognition may be reasonable candidates. 
There are several limitations of this study. First, the sample size is relatively small, especially 
for the viral infection group, although our study had enough power to detect a clinically 
relevant difference between the single and panel analyses. Second, this was a subset 
analysis of a prospective study in patients with LRTI that had a microbiological diagnosis. 
For an explorative study, we deliberately included only patients with a confirmed diagnosis. 
Because of the outbreak of acute Q-fever in the Netherlands between 2007 and 2010 
Coxiella burnetii infections represented a large part of the bacterial pathogens. Patients 
with acute Q-fever are indistinguishable from other bacterial infection on clinical grounds 
[31]. Furthermore, in the present study the distribution of the inflammatory markers was 
not importantly influenced by the inclusion of acute Q-fever patients. Third, viral infections 
predispose to bacterial super infections and these cannot be ruled out in all patients 
diagnosed as having a viral LRTI. In most of the patients admitted to the hospital, because of 
the severity of illness, antibiotic treatment was initiated, making it difficult to determine in 
hindsight the presence or absence of a bacterial co-infection. Fourth, although the results of 
our study may be different in LRTI patients with <2 clinical signs of sepsis, in general practice 
the vast majority of patients with a LRTI fulfil ≥2 of the sepsis criteria and consequently 
satisfy the sepsis definition. Therefore, the results of our study apply to most patients 
presenting with signs of LRTI to the emergency department. Finally, a group of control 
patients with other types of non-infectious inflammatory reactions was not included in our 
cohort, as our primary aim was to investigate whether additional biomarkers could improve 
the differentiation between viral and bacterial LRTI’s and not to determine their value to 
establish the presence of an infection.
In conclusion, while different markers of inflammation show statistically significant higher 
levels in the group of patients with a bacterial infection compared to the patients with a 
viral LRTI, the combination of CRP with LBP, PCT, IL-6, IL-18, or sTREM-1 does not improve 
the prediction of microbiological aetiology in patients with LRTI, when compared with CRP 
as a single marker. Ruling out a bacterial infection remains troublesome and future studies 
should aim to identify better diagnostic markers. 
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ABSTRACT
Background: The extracellular domains of cytokine receptors are released during 
inflammation, but little is known about the shedding of Toll like receptors (TLR) and whether 
they can be used as diagnostic biomarkers. 
Methods: The release of sTLR2 and sTLR4 was studied in in-vitro stimulations, as well as 
in-vivo during experimental human endotoxemia (n=11, 2ng/kg LPS), and in plasma of 394 
patients with infections (infectious mononucleosis, measles, respiratory tract infections, 
bacterial sepsis and candidemia) or non-infectious inflammation (Crohn’s disease, gout, 
rheumatoid arthritis, autoinflammatory syndromes and pancreatitis). Using C-statistics, the 
value of sTLR2 and sTLR4 levels for discrimination between infections and non-infectious 
inflammatory diseases, as well as between viral and bacterial infections was analyzed. 
Results: In-vitro, peripheral blood mononuclear cells released sTLR2 and sTLR4 by exposure to 
microbial ligands. During experimental human endotoxemia, plasma concentrations peaked 
after 2 hours (sTLR4) and 4 hours (sTLR2). sTLR4 did not correlate with cytokines, but sTLR2 
correlated positively with TNFα (rs=0.80, P<0.05), IL-6 (rs=0.65, P<0.05), and IL-1Ra (rs=0.57, 
P=0.06), and negatively with IL-10 (rs=-0.58, P=0.06), respectively. sTLR4 had a similar area 
under the ROC curve [AUC] for differentiating infectious and non-infectious inflammation 
compared to CRP: 0.72 (95% CI 0.66-0.79) versus 0.74 (95% CI 0.69-0.80) [P=0.80], while 
sTLR2 had a lower AUC: 0.60 (95% CI 0.54-0.66) [P=0.0004]. CRP differentiated bacterial 
infections better from viral infections than sTLR2 and sTLR4: AUC 0.94 (95% CI 0.90-0.96) 
versus 0.58 (95% CI 0.51-0.64) and 0.75 (95% CI 0.70-0.80), respectively [P<0.0001 for both]. 
Conclusions: sTLRs are released into the circulation, and our studies suggest the possibility 
to use sTLRs as diagnostic tool in inflammatory conditions
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INTRODUCTION
Toll-like receptors (TLRs) are germline-encoded receptors that recognize microbial structures 
called pathogen-associated molecular patterns (PAMPs), either alone or in combination with 
co-receptors. Besides regulating innate and adaptive immune responses, TLR signaling plays 
an important role in the pathogenesis of several inflammatory diseases, and tight regulation 
is crucial in order to prevent hyperinflammation [1, 2]. Immune signaling is regulated at 
multiple levels, and the release of extracellular domains of immune receptors such as 
cytokine receptors represents an important regulatory mechanisms [3]. Similar negative 
regulation accounts for modulation of TLR function [1, 2], and soluble forms of TLR2 and 
TLR4 have been recently described [4, 5]. The release of these soluble proteins increases 
upon cell activation and they exert inhibitory activity on TLR signaling [4, 5]. Soluble forms 
of TLRs have been detected in pleural fluid, amniotic fluid, saliva, breast milk and plasma 
[4, 6-10]. 
Timely knowledge of the etiology of inflammatory conditions is crucial. Not only does it 
facilitate appropriate treatment, but also unnecessary interventions may be avoided. In light 
of the critical shortage of new antibiotics, reduction in antibiotic prescription is warranted. 
The concept of measuring soluble pattern recognition receptors (PRRs) for the diagnosis of 
infections has been previously proposed for the TLR4-coreceptor CD14 [11, 12]. However, 
analysis of soluble TLRs have up till now only been used in the diagnostic workup of pleural 
effusion and intra-amniotic infections [8-10, 13].
The aim of the present study was to gain more insight into the release of sTLR2 and sTLR4 
in-vitro and to investigate the kinetics of monocytic TLR2 and TLR4 expression and plasma 
levels of their soluble counterparts during experimental endotoxemia (intravenous LPS 
administration in healthy volunteers). Furthermore, we hypothesized that sTLR2 and sTLR4, 
being soluble forms of receptors that play pivotal roles in pathogen recognition by cells of 
the innate immune system, are differentially released during various inflammatory diseases, 
with higher levels in inflammatory conditions of infectious origin. As such, we evaluated 
the ability of sTLR2 and sTLR4 levels to discriminate between infectious and non-infectious 
inflammatory pathologies.
PATIENTS AND METHODS
In-vitro studies
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy 
individuals after informed consent. Briefly, PBMCs were isolated by density gradient 
centrifugation using Ficoll-Paque PLUS (GE Healthcare, Zeist, The Netherlands) and 
collecting the white interphase. Cells were washed twice in cold PBS and concentrations 
were adjusted to 5 × 106 cells/mL in RPMI-1640, supplemented 2 mM l-glutamine, 1 mM 
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pyruvate and 50 μg/ml gentamicin (GIBCO Invitrogen, Carlsbad, CA). Mononuclear cells (5 
× 105) in a 100-μL volume were added to round-bottom 96-well plates (Greiner, Nurnberg, 
Germany) and incubated with either 100 μL of culture medium (negative control), or LPS 
from E. coli O55:B5 (10 µg/mL; Sigma-Aldrich, St Louis, MO), Pam3Cys (10 µg/mL) or heat-
killed E. coli ATCC 35218 (107 micro-organisms/mL).  After 24 hour incubation at 37ºC, the 
supernatants were stored at -80ºC until measurement of sTLR2, sTLR4 and IL-6. 
Experimental human endotoxemia 
This study was part of a larger endotoxin trial registered at the ClinicalTrials.gov registry 
under the number NCT00783068 which was approved by the local ethics committee of 
the Radboud university medical center [14]. The 11 healthy male volunteers included in 
the present study provided written informed consent. Briefly, subjects were prehydrated 
during 1 h before LPS administration by infusion of 1.5 L 2.5% glucose/0.45% saline solution, 
followed by 150 mL/h starting at the time of LPS administration until 6 h afterwards and 75 
mL/h until the end of the experiment. US Reference Escherichia coli endotoxin (LPS derived 
from E. coli O:113; Clinical Center Reference Endotoxin, National Institutes of Health, 
Bethesda, Md) was administered as an intravenous bolus (2 ng/kg). EDTA anticoagulated 
blood was collected from an arterial line. 
Flow cytometry for membrane TLR2 and TLR4 expression
In order to determine expression of TLR2 and TLR4, blood was collected in EDTA-containing 
vacutainers. The following directly conjugated mouse anti-human antibodies were used: 
TLR2: CD282 PE (mouse IgG2a, TLR 2.1 clone, eBioscience, San Diego, CA), TLR4: CD284 PE-
Cy7 (mouse IgG2a, HTA125 clone eBioscience, San Diego, CA), and CD14 ECD (mouse IgG2a, 
RMO52 clone Immunotech, Beckman Coulter, Marseille, France). Isotype and fluorochrome 
matched controls from Beckman Coulter were used. Cell buffer solution was used containing 
0.5% Bovine Serum Albumin in Phosphate Buffered Saline and 0.1% sodium azide. Rabbit 
serum (Invitrogen, Carlsbad, CA) for blocking was diluted to 20% with cell buffer solution. 
Red blood cell lysis was performed using 0.075M ammonium chloride (NH4Cl, pH7.4), 
freshly prepared. 1 mL of blood was mixed with 20 ml of NH4Cl lysing solution and was 
left at room temperature for 10 minutes. After centrifuging for 5 minutes at 500g the 
supernatant was discarded. The cell pellet was resuspended in 50 mL of PBS and centrifuged 
again. After this washing step the cell pellet was resuspended in 0.5 mL cell buffer solution. 
0.1 mL of this cell suspension was mixed with 0.1 mL 20% rabbit serum and left at room 
temperature for 10 min. Subsequently, cells were incubated with the appropriate antibody 
concentration mixture for 15 min in the dark at room temperature. After washing, samples 
were resuspended in 0.5 mL cell buffer solution and analyzed on a Beckman Coulter FC500 
flow cytometer (Beckman Coulter, Miami, FL). Monocytes were gated in a Side Scatter vs. 
CD14 plot. Fluorochrome matched isotype controls, non-stained samples, as well as cells 
incubated with only a secondary antibody, were used to set the photo multiplier detectors. 
The TLR2 and TLR4 expression was analyzed within CD14+ monocytes.
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Table 1. Description of the included inflammatory disorders.
Inflammatory disorder Inclusion criteria Exclusion criteria
Crohn’s disease Compatible endoscopic and histopathologic   findings
Exacerbation 
Before first TNFα-antagonist infusion
-
Rheumatoid arthritis Fulfilling the 1987 ACR criteria
DAS28 >3.2
-
Gout Acute arthritis
Urate crystal positive or previously diagnosed gout
-
Autoinflammatory 
syndrome
Known history of autoinflammatory disorder
Typical attack
-
Pancreatitis [20] Acute characteristic epigastric pain
SIRS [18] 
Serum and urinary amylase levels ≥ 3 x ULN
Compatible imaging (CT or ultrasound) findings
HIV
Neutropenia (< 1000/
mm3)
Chronic corticosteroid 
use
Infectious mononucleosis 
[16] 
Compatible clinical signs
EBV (VCA) or CMV IgM positive 
-
Measles [15] Febrile rash
Measles IgM positive
-
Viral respiratory tract 
infection
Symptoms/signs of respiratory tract infection
Positive PCR from respiratory tract secretions
Positive sputum or 
blood culture
Respiratory co-infections Symptoms/signs of respiratory tract infection
Positive PCR from respiratory tract secretions
Positive sputum or blood culture
-
Bacterial sepsis [17] International sepsis definition [18] HIV
Neutropenia (<1000/
mm3)
Candidemia [19] Positive blood culture for Candida -
Abbreviations: ACR, American College of Rheumatology, DAS28, disease activity score in 28 joints, ULN, upper limit 
of normal, EBV, Epstein-Barr virus, VCA, viral capsid antigen, CMV, cytomegalovirus, ICU, intensive care unit.
Table 2. Demographic characteristics of the healthy controls and patients 
Group Number Age
Years (IQR)
Sex
 % male
Healthy controls 29 24 (20-46) 69
Crohn’s disease 15 36 (21-47) 27
Rheumatoid arthritis 20 60 (53-67) 30
Gout 36 68 (54-75) 83
Autoinflammatory syndrome 15 32 (22-42) 29
Pancreatitis 22 64 (58-72) 80
Infectious mononucleosis 16 31 (22-37) 50
Measles 43 7 (3-12) 43
Viral respiratory tract infection 25 29 (17-42) 52
Respiratory co-infections 20 11 (2-49) 70
Bacterial sepsis 49 75 (49-79) 58
Bacterial severe sepsis 50 74 (59-80) 56
Bacterial septic shock 57 72 (60-78) 56
Candidemia 26 59 (41-71) 69
Abbreviations: IQR, interquartile range.
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Biomarker study
Plasma concentrations of sTLR2 and sTLR4 were measured in healthy controls, and two 
groups of patients  and compared to that of the most used inflammatory biomarker, 
C-reactive protein (CRP). EDTA anticoagulated blood from the various groups of patients was 
prospectively collected during planned laboratory blood assessment for clinical purposes, 
or was available from previous clinical studies, as indicated. Plasma was obtained by 
centrifugation for 10 minutes at 2000g. The study has been carried out in the Netherlands in 
accordance with the applicable rules concerning the review of research ethics committees 
and informed consent. Inclusion and exclusion criteria for the inflammatory disorders are 
shown in Table 1. Table 2 shows the demographic characteristics of the healthy controls and 
the patients included in this study. 
The first group consisted of patients with infectious diseases in whom plasma was obtained 
≤24 hours after presentation: viral lower respiratory tract infections (LRTI) (n=25; Table 3), 
measles [15] (n=43), infectious mononucleosis caused by either Epstein-Barr virus (EBV) 
[16] or cytomegalovirus (CMV) infection (n=16), bacterial and viral respiratory co-infections 
(n=20; Table 3), bacterial sepsis [17], stratified into sepsis, severe sepsis and septic shock 
[18] (n=156), and candidemia [19] (n=26). The second group comprised of patients with 
non-infectious inflammation: Crohn’s disease (n=15), gout (n=36), autoinflammatory 
syndromes (n=15), rheumatoid arthritis (n=20), and pancreatitis [20] (n=22). Patients with 
autoinflammatory syndromes consisted mainly of patients with well-known, genetically 
confirmed autoinflammatory diseases, like hyperimmunoglobulin-D syndrome, familial 
Mediterranean fever, Muckle-Wells syndrome and tumor necrosis factor receptor-1 
associated syndrome (TRAPS). Pancreatitis was of biliary origin in 45%, none developed 
necrosis and all had negative blood cultures. Samples were taken ≤24 hours after 
presentation, except for Crohn’s disease and reumatoid arthritis. Those were taken during 
an exacerbation of the disease (Table 1). The disease activity of rheumatoid arthritis was 
measured with Disease Activity Score (DAS) in 28 joints (DAS28) [21]. The definition of active 
rheumatoid arthritis is a DAS28 >3.2. The mean DAS28 was 4.49 (range 3.40-6.40, of whom 
7 patients had a score >5.1, indicating high disease activity).
Cytokine and sTLR2 and sTLR4 measurement
sTLR2 and sTLR4 concentrations were measured by a commercial ELISA kits (USCN Life 
Science, Inc., Wuhan, China) with a lower limit of detection of 0.312 ng/mL and 0.156 ng/
mL, respectively. A commercial ELISA (Sanquin, Amsterdam, the Netherlands) with a minimal 
detection level of 1.56 pg/mL was used for the determination of Interleukin (IL)-6 concentrations 
in supernatants. IL-6, tumor necrosis factor (TNF)-α, IL-1Ra and IL-10 concentrations in plasma 
were determined using a Luminex assay (Bio-plex cytokine assay, BioRad, Hercules, CA), with a 
sensitivity of 6 pg/mL, 20 pg/mL, 72 pg/mL and 6 pg/mL, respectively. CRP concentrations were 
measured with a commercial ELISA, with a lower detection limit of 5 mg/L (IBL International, 
Hamburg, Germany). Samples were diluted when appropriate.
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Table 3. Demographic and clinical characteristics of the patients with viral  respiratory tract infections (n=25) and 
bacterial and viral respiratory co-infections (n=20).  
Variable Viral Bacterial
Male/Female (% male) 13/12 (52) 14/6 (70)
Age, yrs [median (IQR)] 29 (17-42) 11 (2-49)
Admission to the hospital ward, no (%) 14 (56) 20 (100)
ICU admission, no (%) 1 (4) 13 (65)
Comorbidities
   None, n (%) 9 (36) 6 (30)
   Diabetes mellitus, n (%) 1 (4) 0 (0)
   Chronic obstructive pulmonary disorder or asthma, n (%) 7 (28) 3 (15)
   Chronic renal disease, n (%) 1 (4) 2 (10)
   Solid or hematological malignancy, n (%) 6 (24) 6 (30)
   Cardiovascular disease, n (%) 3 (12) 2 (10)
   Other, n (%) 5 (20) 6 (30)
Viral pathogen
   Influenza virus, n (%) 17 (68) 7 (35)
   Respiratory syncythial virus, n (%) 0 (0) 6 (30)
   Parainfluenza virus, n (%) 3 (12) 5 (25)
   Coronavirus, n (%) 2 (8) 0 (0)
   Human metapneumovirus, n (%) 1 (4) 0 (0)
   Adenovirus, n (%) 0 (0) 2 (10)
   Parecho-/rhinovirus, n (%) 1 (4) 0 (0)
   Respiratory syncythial/rhinovirus, n (%) 1 (4) 0 (0)
Bacterial pathogen
   S. aureus, n (%) 0 (0) 5 (25)
   S. pneumonia, n (%) 0 (0) 3 (15)
   P. aeruginosa, n (%) 0 (0) 4 (20)
   S. pneumoniae/H. influenzae, n (%) 0 (0) 2 (10)
   S. pneumonia/M. catarrhalis, n (%) 0 (0) 1 (5)
   Other (combinations), n (%) 0 (0) 5 (25)
28-day mortality, n (%) 1 (4) 3 (15)
Abbreviations: n, number, IQR, interquartile range, ICU, intensive care unit.
Statistical analysis
Cytokine and sTLR concentrations in the in-vitro and endotoxemia experiments are expressed 
as mean ± SEM. For the assessment of correlations Spearman correlation coefficient was 
calculated. The Mann-Whitney U test was used for the comparison of two groups in the 
biomarker study. Additionally, to correct for the potential influence of age and sex on the 
biomarker concentrations, we performed multiple linear regression analysis (forced entry 
method) with the biomarker of interest as dependent variable and age, sex and the assigned 
group (infection/no infection or bacterial/viral infection) as independent variable. Receiver 
operating characteristics (ROC) curve statistics were applied to calculate sensitivity and 
specificity. In order to determine the diagnostic accuracy of the combination of biomarkers, 
logistic regression analysis was used to estimate the predicted probabilities, which were 
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subsequently used for the generation of a ROC curve. The method described by DeLong 
was used for comparing areas under ROC curves (AUC) [22]. All tests were two-sided, and 
P<0.05 was considered statistically significant. Data were analyzed using Graph Pad Prism 
5 (GraphPad Software, La Jolla, CA) and MedCalc version 11.3.1.0 (MedCalc Software, 
Mariakerke, Belgium).
RESULTS
In-vitro release of soluble TLRs by human PBMCs
sTLR2 and sTLR4 were below the detection limit (6 and 8 ng/mL, respectively) in the 
supernatants of unstimulated PBMCs. After stimulation with LPS, Pam3Cys or heat-killed 
E. coli, significant amounts of IL-6, sTLR2 and sTLR4 were released by PBMCs into the 
supernatant, although shedding of sTLRs was not confined to stimulation of its corresponding 
cell surface receptor (Figure 1). 
sTLR2 and sTLR4 release during human endotoxemia 
sTLR2 and sTLR4 plasma concentrations displayed a distinct pattern after LPS infusion 
(Figure 2). Before LPS administration, sTLR2 and sTLR4 levels were undetectable or low 
in all volunteers. sTLR4, TNFα, IL-6 and IL-10 concentrations increased after LPS infusion 
Figure 1. Release of IL-6, sTLR2 and sTLR4 after stimulation for 24 hours of peripheral blood mononuclear cells with 
either medium (control) or a microbial stimulus. Data are expressed as means ± SEM (n= 6). The concentrations of 
IL-6, sTLR2 and sTLR4 after incubation with medium are below the detection limit.
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and reached a peak concentration at 2 hours LPS infusion; sTLR2 and IL-1Ra peaked after 
4 hours. The mean peak values (± SEM) were 357 ± 94 ng/mL for sTLR2, 10.5 ± 2.3 ng/mL 
for sTLR4, 836 ± 288 pg/mL for TNF-α, 926 ± 145 pg/mL for IL-6, 90 ± 17 pg/mL for IL-10, 
and 26081 ± 2213 pg/mL for IL-1Ra, respectively. The AUC of sTLR4 showed no correlation 
with the AUCs of sTLR2 (rs 0.03, P=0.94), IL-6 (rs -0.07, P=0.83), TNF-α (rs -0.07, P=0.80), IL-
10 (rs 0.22, P=0.52), and IL-1Ra (rs 0.14, P=0.69). However, sTLR2 showed a strong positive 
correlation with TNF-α (rs 0.80, P=0.003), IL-6 (rs 0.65, P=0.03). sTLR2 showed a trend 
towards a positive correlation with IL-1Ra (rs 0.57, P=0.06), and a negative with IL-10 (rs 
-0.58, P=0.06), respectively.
Cell-surface expression of TLR2 and TLR4 on monocytes varied extensively among the 
subjects without a clear pattern and did not correlate with sTLR2 and sTLR4 plasma levels 
(Figure 2).
Figure 2. Mean (± SEM) plasma concentrations of TNF-α, IL-6, IL-10, sTLR2, sTLR4 and IL-1Ra after administration of 
LPS intravenously in 11 healthy volunteers (upper 6 panels). Lower panels show mean change (± SEM) in expression 
of TLR2 and TLR4 on CD14+ monocytes (mean fluorescence intensity (MFI)) compared to baseline after injection of 
LPS.
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Circulating concentrations of sTLR2 and sTLR4 in various inflammatory diseases
Figure 3 shows the circulating concentrations of CRP, sTLR2 and sTLR4 in various infectious 
and non-infections inflammatory diseases. 394 patients and 29 healthy volunteers were 
included. For determination of CRP, samples of 351 patients and 11 healthy volunteers 
were analyzed. CRP, sTLR2 and sTLR4 circulating concentrations were significantly higher 
in patients with infection compared with patients with non-infectious inflammation (Figure 
4, groups A and B). After correction for age and sex, the presence of an infection was still 
positively associated with CRP, sTLR2 and sTLR4: unstandardized coefficients 85 (95% CI 64-
106, P<0.001), 23 (95% CI 12-34, P<0.001), and 6.2 (95% CI 4.2-8.2, P<0.001), respectively. 
Age, but not sex, was also positively associated with the three biomarker concentrations. 
Furthermore, compared with patients suffering from viral infections, patients with bacterial 
infections displayed higher concentrations of CRP and sTLR4, but not sTLR2 (Figure 4, groups 
C and D). Multivariate analysis with correction for age and sex showed all three biomarkers 
to be independently associated with the presence of a bacterial infection. Unstandardized 
coefficients for CRP, sTLR2 and sTLR4 were 113 (95% CI 79-147, P< 0.001), 19 (95% CI 0.2-
39, P=0.04) and 6.2 (95% CI 2.2-9.0, P=0.01), respectively. Neither sex, nor age proved to 
influence the concentrations of CRP, sLTR2 and sTLR4.
Figure 3. Concentrations of CRP, sTLR2 and sTLR4 for the individual patient groups as described in the right upper 
panel. The median is reported above the plots in the different figures, the number of patients under the X-axis.
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In the patients with bacterial or fungal sepsis, the presence of a malignancy (n=27; without 
malignancy n=155) was associated with higher concentrations of CRP (152 vs 127 mg/l, 
P=0.07), sTLR2 (62 vs 23 ng/ml, P=0.001) and sTLR4 (7.2 vs 4.3 ng/ml, P=0.15), although this 
only reached statistical significance for sTLR2. 
Table 4. AUC of the ROC for the discrimination between an infection and non-infectious inflammation and between 
bacterial and viral infection. 
Biomarker Infection vs No infection
AUC (95% CI)
P-valuea Bacterial infection vs Viral infection
AUC (95% CI)
P-valuea
CRP 0.74 (0.69-0.80) - 0.94 (0.90-0.96) -
sTLR2 0.60 (0.54-0.66) 0.0004 0.58 (0.51-0.64) <0.0001
sTLR4 0.72 (0.66-0.79) 0.80 0.75 (0.70-0.80) <0.0001
sTLR2 + sTLR4 0.65 (0.60-0.70) 0.01 0.75 (0.69-0.80) <0.0001
sTLR2 + CRP 0.75 (0.70-0.80) 0.66 0.94 (0.90-0.96) 0.36
sTLR4 + CRP 0.76 (0.71-0.80) 0.25 0.95 (0.91-0.97) 0.13
Abbreviations: AUC area under the curve, CI confidence interval.
aP-value for the comparisons of the AUCs with the AUC of CRP.
The discriminative value of sTLR4 levels to identify infectious versus non-infectious 
inflammation was similar compared with CRP: AUC of 0.72 (95% CI 0.66-0.79) and 0.74 
(95-% CI 0.69-0.80), P=0.80 (Table 4, Figure 5). sTLR2 performed worse: AUC 0.60 (95% 
CI 0.54-0.66), P=0.0004 compared to the AUC of CRP. At a specificity of 95%, circulating 
Figure 4. Comparison of plasma concentrations of CRP, sTLR2 and sTLR4 in patients with infections (A) versus 
non-infectious inflammatory diseases (B) (upper panel) and in patients with a bacterial infection (C) versus a viral 
infection (D) (lower panels). The Mann-Whitney U test was used for the comparison of two groups. P-values are 
shown above the graphs. The median is reported above the corresponding plot.
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concentrations of sTLR2 above 47 ng/mL, sTLR4 above 18.9 ng/mL, and CRP above 150 
mg/L had a sensitivity of 32%, 16% and 28%, respectively, to identify an infectious process. 
Combination of biomarkers showed no improvement of the AUC (Table 4).
CRP levels showed good value to discriminate between bacterial and viral infections 
with an AUC of 0.94 (95% CI 0.90-0.96). sTLR4 levels displayed a significantly lower AUC 
compared with CRP: 0.75 (95% CI 0.70-0.82), P<0.0001. sTLR2 was a poor discriminator 
between patients with a bacterial or viral infection (Table 4, Figure 5). Panel analysis with 
two biomarkers was similar to the performance of CRP alone. The cutoff values for the 
discrimination of bacterial infections from viral infections with a specificity of 95% were for 
CRP 67 mg/L (sensitivity 82%), for sTLR2 79 ng/mL (sensitivity 23%) and for sTLR4 10.6 ng/
mL (sensitivity 28%).
DISCUSSION
In the present study, we demonstrate that sTLR2 and sTLR4 are released in-vitro and in-
vivo after challenge with microbial ligands such as LPS. Significantly elevated plasma 
concentrations of sTLRs are present in the circulation during experimental human 
endotoxemia, and high circulating concentrations of sTLR4 are found in patients with 
infections compared to patients with non-infectious inflammation, as well as in patients 
with bacterial infections compared with viral infections. However, the value of sTLR2 and 
sTLR4 as additional diagnostic biomarkers is low as both new markers do not surpass CRP 
in accuracy
Figure 5. ROC curves of CRP, sTLR2 and sTLR4 for the comparison between patients with infections and non-
infectious inflammation (left panel) and between patients with a bacterial and viral infection (right panel). AUCs are 
shown between brackets. P-values indicate the comparison  of the AUC of sTLR2, sTLR4 and CRP.
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In addition to the release of sTLR2 and sTLR4 from stimulated immune cells [4, 5], constitutive 
release of sTLRs has been demonstrated in various biological fluids such as saliva, breast 
milk, and amniotic fluid [10, 23]. In plasma, sTLR2 represented by several polypeptides, has 
been found by others [4], although the concentrations are low. To avoid both harmful or 
insufficient inflammatory responses, inhibition and activation of the immune system needs 
to be properly balanced. Various negative regulators of TLRs have been described [1] of 
which sTLR2 and sTLR4 constitute an important first-line negative regulatory mechanism [4-
6, 23-25]. sTLR2 either interferes with CD14-mediated triggering of membrane-bound TLR2, 
dimerizes with TLR2 on the cell surface, or competes with cellular TLR2 for microbial ligands 
[4]. The complex formed by sTLR4 and MD-2 probably blocks the interaction between 
membrane-bound TLR4 and its ligand [25]. The rapid elevation of sTLR2 and sTLR4 in plasma 
upon LPS administrations, similar to that of pro-inflammatory cytokines, indicates that this 
feedback mechanism is rapidly activated. Consistent with our in-vitro data, the release of 
sTLRs in the circulation demonstrates that immune modulation mediated by TLRs is not 
limited to the stimulation of the corresponding receptor on the cell membrane of immune 
cells. Since both sTLR2 and sTLR4 dampen inflammation by disrupting TLR-mediated pro-
inflammatory responses [4-6, 23-25], it might also be possible that the counter regulatory 
mechanisms mediated by soluble TLRs extend to interference with endogenous TLR ligands. 
Although the kinetics of sTLR2 and sTLR4 concentrations parallel those of anti-inflammatory 
cytokines, quantitatively they appear to be differentially regulated. Plasma sTLR4 levels did 
not show any correlation with both IL-10 and IL-1Ra and for sTLR2, a negative correlation with 
IL-10 was found. Interestingly, while in-vitro release of sTLR2 and sTLR4 by immune cells is 
comparable, their in-vivo concentrations differ strongly, with much higher concentration in 
the circulation of sTLR2: this suggests a much more rapid clearance of sTLR4 from circulation. 
This may imply that these anti-inflammatory mechanisms are regulated at a different level 
and are potential complementary strategies to reduce inflammation.
In recent years, an important role for TLR signaling has been discovered in oncogenesis, 
particularly in inflammation-driven tumors [26]. Although the relationship between 
cell-bound TLR2 and its release as a soluble form is not clear-cut, the observed higher 
concentrations of sTLR2 in the (small) group of patients with an underlying malignancy may 
reflect the increased expression of TLR2 as seen in some forms of cancer [26].
Alternatively spliced TLR4 mRNA encodes the soluble form of TLR4 [5]. As such, we did not 
expect a correlation between the membrane expression of TLR4 and circulating sTLR4. On 
the contrary, sTLR2 results from posttranslational processing: endocytosis of cell surface 
receptor is followed by conversion into sTLR2 intracellularly [4]. In previous monocyte 
stimulation experiments, membrane-bound TLR2 correlated negatively with supernatant 
sTLR2 [4]. We did not observe the downregulation of cell surface TLR expression on 
monocytes of individuals during endotoxemia. Possible explanations for this lack of 
correlation are that (1) monocytes are detected only in very low numbers at 2 hours after 
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LPS injection [27] and this subpopulation may well have a different TLR expression than 
more active monocytes that have marginated at this time-point; (2) we only examined the 
expression of TLRs on monocytes (CD14+), however, other circulating cell subsets such as 
neutrophils or platelets also express TLR2 [28, 29], all potentially contributing to the plasma 
concentrations of sTLRs; (3) the soluble receptors are derived from an intracellular pool, not 
directly from the cell surface [4]; and finally (4) besides being shed, membrane bound TLR 
is influenced by TLR trafficking between intracellular compartments and the cell membrane 
[30]. 
An important aspect of this study is the possibility to use soluble TLRs as diagnostic markers. 
Rapid and reliable differentiation of non-infectious inflammatory disorders from infections, 
and the classification of infections according to their microbiological etiology is essential 
for optimal treatment of these conditions. So far, only a small number of studies have been 
published on soluble TLRs as diagnostic biomarkers. A few studies from the same group 
reported that intrauterine infections in pregnant women are characterized by elevated levels 
of sTLR1, sTLR2, sTLR6 and sTLR4 in the amniotic fluid [9, 10, 13], supporting the concept 
of soluble TLR release during infections. We assessed the value of sTLR2 and sTLR4 levels 
to discriminate between several inflammatory conditions. sTLR2 and sTLR4 were elevated 
in response to inflammatory insults and particularly sTLR4 showed a good specificity to 
discriminate between an infection and a non-infectious inflammatory condition such as 
gout, Crohn’s disease, rheumatoid arthritis or autoinflammatory syndromes. Moreover, 
sTLR4 concentrations show a high specificity for discriminating between bacterial and viral 
infections using high cutoff values, but sensitivity was low. We have to mention however 
that the overall discriminative value of sTLR levels was not superior to that of CRP in the 
relatively small group of patients assessed in this study. Future larger validation studies 
should demonstrate the overall value of sTLR2 and sTLR4 levels for the diagnosis of 
infections and autoinflammatory diseases in relation to that of classic inflammatory markers. 
Furthermore, besides TLRs, other soluble pattern recognition receptors such as the soluble 
mannose receptor that are shed during cell stimulation with β-glucans are also interesting 
candidates for new and potentially more specific diagnostic biomarkers [31]. 
Our study also has limitations. Firstly, it included a relatively limited number of clinical 
conditions, and it is not possible to extrapolate our results to the entire panel of infectious 
or non-infectious inflammatory diseases. Secondly, we studied groups of inflammatory 
conditions as a whole, rather than focusing on correlation with other clinical information 
or outcome. 
In conclusion, the present study is an important initial proof-of-principle report on the 
role of sTLR2 and sTLR4 during a broad panel of human infections and autoinflammatory 
diseases. Shedding of sTLR2 and sTLR4 is not confined to stimulation of its corresponding 
cell surface receptor, but it is a broader effect upon stimulation of innate immune cells 
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through pattern recognition receptors. We report the significant increase of sTLR2 and 
sTLR4 both in experimental models of human endotoxemia, as well as in the circulation of 
patients with infections. This suggests an important role of soluble TLRs in the modulation 
of inflammation during infections and the potential to use these tests as diagnostic markers. 
Therefore, larger validation studies in larger patient cohorts are warranted in order to be 
able to draw definitive conclusions regarding the diagnostic usefulness of sTLR2 and sTLR4 
in human inflammatory diseases.
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ABSTRACT
Background: Recent studies point out to a dual role for galectin-3 as both circulating damage-
associated molecular pattern and cell membrane-associated pattern recognition receptor. 
The aim of this study was to assess the potential of circulating galectin-3 for discriminating 
between infections and non-infectious inflammatory disorders (NIID) on the one hand, and 
between fungal and bacterial infections on the other hand.
Methods: Galectin-3 and C-reactive protein (CRP) were measured in plasma of 127 patients 
with either NIID (gout, autoinflammatory syndrome or pancreatitis) or an infection (viral 
lower respiratory tract infection, bacterial sepsis or candidemia). 
Results: Circulating galectin-3 concentrations were increased in patients with infections, 
when compared with healthy volunteers or patients with NIID. At cutoff values with a 
specificity of 95%, the sensitivity of galectin-3 (>20.6 ng/mL) for the presence of an infection 
was higher than that of CRP (>156 mg/L): 43% (95% CI 33-53%) versus 27% (95% CI 19-37%), 
P=0.03. After exclusion of patients with CRP<156 mg/L, galectin-3 concentration >20.6 ng/
mL could identify 41% (95% CI 29-53%) of the patients with an infection at the cost of one 
false positive with non-infectious inflammation. Using this sequential approach, 57% of 
the patients with an infection could be selected. Galectin-3 concentrations were similar in 
patients with bacterial and Candida sepsis, while being lower in viral respiratory infections.
Conclusions: Although galectin-3 does not discriminate between bacterial and Candida 
sepsis, sequential use of CRP and galectin-3 in distinguishing infectious diseases from non-
infectious inflammation may be superior to CRP alone.
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INTRODUCTION
Galectin-3, a member of the β-galactoside binding galectin family, is uniquely chimeric, has 
a broad tissue distribution and is found in cells involving the immune response [1]. This 
multifunctional carbohydrate binding protein is implicated in many biological functions, both 
intracellulary and extracellularly [1, 2]. After passive release from damaged cells or through 
active secretion, extracellular galectin-3 can cross-link specific ligands on cell surfaces 
inducing intercellular communication and influencing cell signalling [3, 4]. Subsequently, 
galectin-3 modulates immune responses either as damage-associated molecular pattern 
or as pattern recognition receptor [2]. As the receptor for β-1,2 mannoside [5], a cell wall 
component of Candida albicans, galectin-3 is essential for the anti-Candida host-response 
[6]. In models of Candida albicans infection, galectin-3 leads to increased TNF-α production 
after cross-talk with TLR-2 [7] and dectin-1 [8], and galectin-3 has been shown to have direct 
antifungal properties [9]. 
Despite these important biological effects and the known capacity of immune cells to release 
galectin-3 during stimulation, little is known regarding the diagnostic potential of galectin-3. 
In the present study, we explored the capacity of circulating galectin-3 concentrations to 
discriminate infections from non-infectious inflammation. In addition, because of its known 
importance for antifungal host defence, we assessed whether circulating concentrations of 
galectin-3 are differentially elevated during candidemia or bacterial sepsis. 
PATIENTS AND METHODS
Patients
To assess the capacity of galectin-3 to serve as a biomarker discriminating between different 
inflammatory states, plasma concentrations of galectin-3 were measured in 127 patients with 
either an infection or non-infectious inflammation. C-reactive protein (CRP) concentrations 
were used as reference test. The included conditions were: gout (n=10), exacerbation of 
autoinflammatory syndrome (n=12), pancreatitis (n=10), viral lower respiratory tract 
infections (n=16), bacterial sepsis (n=49) and candidemia (n=30).
Blood was drawn within 24 hours of presentation, except for the patients with candidemia in 
which blood sampling took place between 0 and 3 days after the first positive blood culture.
Supplementary plasma was obtained during planned blood collection for clinical purposes 
or from historical cohorts. Because of the lack of any consequence for the involved patients, 
the medical ethical committee waived the need for informed consent.
Biomarker analysis
CRP and galectin-3 concentrations were measured with commercial ELISAs (IBL International, 
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Hamburg, Germany and R&D Systems, Minneapolis, MN, respectively), with a lower 
detection limit of 5 mg/L and 1.57 ng/mL.
Statistical analysis
Individual concentration and the medians of the biomarkers are displayed in the graphs. 
Where appropriate, the Mann-Whitney U test and the Kruskall-Wallis test with Dunn’s post 
test were used for the comparison of different groups. Spearman correlation coefficient was 
calculated for the correlation between CRP and galectin-3. For analysis of discriminative 
power, ROC curve statistics were applied for each single marker in order to calculate area 
under the curve (AUC), sensitivity and specificity. Cutoff values of CRP and galectin-3 leading 
to specificity higher than 95% were determined. Sensitivity was compared between the two 
biomarkers with the use of the McNemar’s test. 
The combination of biomarkers was tested using two methodologies. Firstly, in order to 
determine the diagnostic accuracy of CRP and galectin-3 together (panel analysis), logistic 
regression analysis was used to estimate the predicted probabilities for CRP and galectin-3 
alone and in a model with both markers combined. These data were used for the generation 
of a ROC curve. Secondly, AUC, sensitivity and specificity of galectin-3 were calculated in 
the subgroup(s) of patients (sequential analysis) with a CRP concentration not predictive for 
the presence of an infectious state or fungal infection (i.e. specificity <95%). The method 
described by Hanley and McNeil was used for comparing the areas under ROC curves [10]. 
All tests were two-sided, and P<0.05 was considered statistically significant. Data were 
analyzed using Graph Pad Prism 5 (GraphPad Software, La Jolla, CA) and MedCalc version 
11.3.1.0 (MedCalc Software, Mariakerke, Belgium).
RESULTS
Main analysis
Median concentration of galectin-3 in five healthy adults was 6.8 ng/mL (range 3.3 -11.0). 
The distribution of galectin-3 concentrations in the circulation of the various patient groups 
is depicted in Figure 1. The median age of the patients was 55 years, 58% was male and 28% 
used immunosuppressive drugs. The demographic and clinical characteristics of the patients 
with candidemia were published previously [11]. Bacterial sepsis and fungal infections did 
not differ significantly with respect to galectin-3 concentrations (P=0.12). Both galectin-3 and 
CRP concentrations were higher during infections than during non-infectious inflammation, 
and the AUC was similar: galectin-3 AUC 0.73; 95% CI 0.64-0.80 versus CRP AUC 0.80; 95% 
CI 0.71-0.86, P=0.27 (Figure 2). Combination of the biomarkers together in a panel did not 
increase the AUC: 0.81 (95% CI 0.73-0.88), P=0.7 (compared with CRP). CRP and galectin-3 
correlated poorly: rs = 0.35, p<0.0001.
Sequential analysis 
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Concentrations of galectin-3 >20.6 ng/mL and CRP >156 mg/L were >95% specific for 
an infectious origin of the inflammation (Figure 2). Interestingly, more patients could 
be identified as having an infection by using galectin-3 than by using CRP: 41 versus 26 
[sensitivity 43% (95% CI 33-53%) for galectin-3 versus 27% (95% CI 19-37%) for CRP (P=0.03)]. 
In the subgroup of patients with CRP <156 mg/L (n=100), galectin-3 had an AUC of 0.71 (95% 
CI 0.61-0.79) and the cutoff value of 20.6 ng/mL had a specificity of >95% for the presence 
of an infection, with a sensitivity of 41% (95% CI 29-53%) (Figure 3). Using the sequential 
analysis of CRP and galectin-3, 54 patients, almost all suffering from a bacterial or fungal 
infection, of the 95 patients with an infection (57%) could be identified accurately.
Prognostic value of galectin-3 in bacterial sepsis patients
Of the 49 patients with bacterial sepsis, 35% had primary bacteremia, 31% pneumonia, 15% 
pyelonefritis, 13% intra-abdominal infection, 4% catheter-related bloodstream infection 
and 2% endocarditis. Fifty-nine percent of the patients (n=29) were bacteremic, of which 
eight had a Gram-positive infections and 21 a Gram-negative infection. Median galectin-3 
concentrations did not differ between these two groups: 15.0 ng/mL (IQR 11.9-27.8) in the 
Gram-positive group versus 30.0 ng/mL (IQR 18.4-35.2) in the Gram-negative group, P=0.10. 
Immunosuppressive treatment did not affect galectin-3 levels either: immunocompromised 
patients had a median concentration of 33.7 ng/mL (IQR 19.6-40.1) compared to 20.1 ng/mL 
(IQR 13.9-34.3) in the patients without immunosuppressants, P=0.12. Figure 3C shows the 
association between the magnitude of values and the severity of the infection in patients 
with sepsis, severe sepsis and septic shock. Although patients with septic shock had higher 
median galectin-3 concentrations, individual concentrations were hardly discriminative. 
Thirty-five percent of the patients died and, despite significant overlap between survivors 
Figure 1. Plasma concentrations of galectin-3 (panel A) and CRP (panel B) in 127 patients with gout (A, n=10), 
autoinflammatory syndrome (B, n=12), pancreatitis (C, n=10), viral lower respiratory tract infections (D, n=16), 
bacterial sepsis (E, n=49) and candidemia (F, n=30).  Medians are shown by grey horizontal bars and are displayed 
above the corresponding columns.
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and non-survivors, mortality was associated with a higher concentration of galectin-3 (Figure 
3D), while CRP concentrations were similar both groups: 112 mg/L (IQR 72-170) versus 114 
mg/L (IQR 78-184), respectively, P=0.82.
DISCUSSION
Our study demonstrates that in patients with signs of inflammation, the addition of 
galectin-3 to CRP measurement significantly increases the number of patients identified 
as having an infection. However, galectin-3 concentration could not discriminate between 
fungal and bacterial sepsis. 
Galectin-3 reaches detectable plasma levels in healthy individuals [12] and due to its 
important role in inflammation [1], fibrosis [12] and cancer [13], several studies investigated 
Figure 2. Plasma concentration of CRP (panel A) and galectin-3 (panel B) in patients with non-infectious inflammatory 
conditions (A, n=32) and infections (B, n=95). Medians are shown by grey horizontal bars and are displayed above 
the corresponding columns. ROC curves for CRP, galectin-3 and the combination of CRP and galectin-3 for the 
presence of infection are shown in panel C. Panel D depicts the probability of infection against the plasma 
concentration of CRP and galectin-3 as calculated with logistic regression analysis.
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its role as biomarker. In chronic heart failure, circulating galectin-3 is an independent marker 
for ventricular remodeling and mortality [14], and circulating levels have been described 
to be higher in cancer patients compared to healthy controls, with a further increase in 
case of metastatic disease [15]. Furthermore, high galectin-3 concentrations predict all 
cause mortality in the general population [12]. However, the clinical benefit of galectin-3 
as a soluble biomarker in the diagnostic process of infections is largely unknown. To this 
end, we measured galectin-3 in various inflammatory diseases and found its release to be 
differentially regulated, with high concentrations being specific for infections of bacterial 
and fungal origin. 
Candidiasis is an increasingly important nosocomial infection with a high mortality [16]. 
Prompt administration of appropriate antifungal therapy is associated with improved 
Figure 3. Plasma concentrations (panel A) and ROC curve (panel B) of galectin-3 in patients (n=100) with CRP 
concentration less than 156 mg/l. The lower panels show the plasma concentrations of galectin-3 in 49 patients 
with bacterial sepsis, divided into three groups of increasing severity: sepsis, severe sepsis and septic shock 
(panel C) and in and survivors versus non-survivors (panel D).  Medians are shown by grey horizontal bars and are 
displayed above the corresponding columns.
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survival [17]. Since blood cultures are neither a fast nor a sensitive tool, clinical prediction 
rules were developed to identify the patients at risk [18] and biomarkers were evaluated 
that can indicate a developing Candida infection [19]. These biomarkers are mostly 
circulating fungal cell wall components or antibodies directed against these antigens, but 
they lack sufficient sensitivity and specificity to diagnose fungal infections efficiently. In the 
present study we used a different approach and hypothesized that an important element 
of anti-Candida fungal immunity, galectin-3, may prove to be useful in the diagnostic work-
up of suspected invasive candidiasis. However, although we demonstrate its release during 
fungal infections, galectin-3 turned out to be a more promiscuous biomarker, which shows 
increased circulating concentration in both bacterial and fungal infection. Similarly, within 
the bacterial infections, different microorganisms elicited a comparable galctin-3 response. 
Both galectin-3 and CRP showed the same pattern of circulating concentrations across 
the six different groups of inflammatory disorders, with higher concentrations present in 
bacterial and fungal sepsis patients compared to patients with non-infectious inflammatory 
conditions or viral infections. However, at the same level of specificity, galectin-3 identified 
more patients with a bacterial or fungal infection than CRP. In the era of increasing 
incidence of sepsis, it is of utmost importance to identify these patients rapidly from 
patients with non-infectious inflammatory conditions in order to initiate the appropriate 
treatment immediately. Therefore, we aimed to increase the sensitivity with the use of 
both biomarkers. Since a concentration of CRP higher than 156 mg/L was almost exclusively 
observed in patients with (bacterial or fungal) infections, we subsequently focused on 
the group of patients potentially most benefitting from combination of biomarkers (i.e. 
patients with CRP < 156 mg/L). Despite the similar profile of both soluble proteins in the 
six groups of patients, this sequential analysis using CRP and galectin-3 had an improved 
sensitivity compared to CRP alone and as such this approach significantly selects more 
patients having an infection than with the use of a single biomarker. The lack of a strong 
correlation between CRP and galectin-3 most likely accounts for this effect: galectin-3 
has added value in the patients with infections in which CRP is low and vice versa. This 
suggests a different underlying pathophysiological mechanism being responsible for the 
release of both molecules. Despite this improvement, more than half of the patients could 
not be categorized adequately even when using a combination of the two markers, since 
moderately elevated biomarker concentrations were also observed in the patients with non-
infectious inflammatory diseases.  The considerable overlap in the lower range precludes 
ruling out an infection with the studied biomarkers, which, in the era of antibiotic resistance 
and shortage, is also of great importance. Furthermore, although galectin-3 was more 
elevated in the non-survivors, individual prediction of survival was cumbersome.
The present study also has limitations. One limitation is that we were able to include a 
relatively limited number of clinical conditions. Thus, the diagnostic value of galectin-3 
should be confirmed in prospective studies including a broader panel of infections and 
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autoimmune diseases. Secondly, the number of patients included in the study for each 
clinical condition was relatively limited, and larger studies are warranted. Finally, in this 
study we used a solely a combination of galectin-3 with CRP, and additional combinations 
may prove even more effective (e.g. with procalcitonin). 
In conclusion, the present study shows that the addition of galectin-3 to CRP improves 
the capacity to predict an infectious origin of the inflammation, when compared with CRP 
as a single biomarker. However, galectin-3 circulating concentrations are similar during 
severe bacterial and invasive candidiasis, precluding its use as a fungal biomarker. Larger 
prospective studies are warranted to fully assess the diagnostic potential of galectin-3.
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ABSTRACT
Background: Nitric oxide (NO) is a key mediator in the pathophysiology of septic shock that 
can be measured in exhaled breath. We aimed to assess whether a pulmonary infection 
itself or systemic inflammation is responsible for exhaled NO. 
Methods: We determined exhaled NO in ventilated patients with respiratory and non-
respiratory septic shock and compared it with the concentration in ventilated intensive care 
patients without systemic inflammation. In addition, the change of NO production over time 
and correlations with hemodynamic instability were evaluated. 
Results: The controls without systemic inflammation, as witnessed by the absence of 
systemic inflammatory response syndrome criteria and low levels of Interleukin-6, had similar 
concentrations of NO as the patients with non-respiratory septic shock. The respiratory 
sepsis patients exhaled more NO than the non-respiratory sepsis patients (P=0.05), and a 
time dependent decline existed in both groups (P=0.04). Exhaled NO did not correlate with 
markers of disease severity, systemic inflammation and hemodynamic instability. 
Conclusions: These data indicate that the infected lungs are the source of exhaled NO. 
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INTRODUCTION
Despite extensive research, septic shock continues to be a devastating disease with a high 
mortality. Apart from increased capillary permeability and cardio-depression, a decrease 
in vascular resistance is mainly responsible for acute circulatory failure leading to organ 
hypoperfusion. An important role in the development of this vasodilatory state has been 
ascribed to nitric oxide (NO) [1]. Endothelial NO synthase (eNOS) produces low concentrations 
of NO that is an important mediator of vascular homeostasis, whereas high levels of NO, 
produced by the increased activity of the inducible isoform of NO synthase (iNOS), exert 
deleterious effects and represents a hallmark of sepsis [2, 3]. Binding of NO to the haem 
group of soluble guanylate cyclase leads to formation of cyclic guanosine monophosphate 
and the subsequent relaxation of vascular smooth muscle cells. Contrary to data obtained in 
various animal studies, ongoing iNOS-mediated NO production does not appear to account 
for the persistence of hypotension in humans [4], and there are indications that in human 
septic shock iNOS activity is compartmentalized at the site of infection [5, 6]. 
After the first demonstration of the presence of NO in exhaled air in 1991 [7] the measurement 
of fractional exhaled NO evolved rapidly. Exhaled NO is studied in several inflammatory lung 
diseases, particularly asthma, with or without nasal polyposis [8], in which it is adopted as 
a non-invasive method to diagnose and monitor disease activity [9] and pharmacological 
treatment [10, 11]. Studies on exhaled NO in intensive care patients with infections are 
scarce [12-14]. In mechanically ventilated patients with pneumonia a significantly higher 
concentration of exhaled NO was found compared to patients without pneumonia [13]. It is 
unclear, however, if the lungs are the primary source of exhaled NO, or if it merely reflects 
pulmonary clearance of NO produced elsewhere in the body during systemic inflammation 
in sepsis patients. To this end, we determined exhaled NO in ventilated patients with septic 
shock due to pneumonia, and compared them with patients in whom sepsis originated from 
a non-respiratory infection and with ventilated ICU patients without signs of inflammation. 
In addition, the change of NO production over time and correlations with haemodynamic 
instability were evaluated.
PATIENTS AND METHODS
Study cohort
The present study was a prospective single center study, performed at the medical and 
surgical intensive care units (ICU) of a university hospital in the Netherlands. Between 
December 2010 and March 2012 all intubated and mechanically ventilated patients with 
septic shock were eligible to participate in this study. Septic shock was defined as the 
presence of systemic inflammatory response syndrome (SIRS) in response to a documented 
infection with signs of organ hypoperfusion or organ dysfunction and acute circulatory 
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failure characterized by requirement of vasopressor therapy [15]. Patients with a history and 
physical examination compatible with a respiratory tract infection and with a consolidation 
on chest X-ray were classified as having a pneumonia. The others were categorized into the 
group of patients with septic shock due to other causes than pneumonia. The control group 
without systemic inflammation (‘non-inflamed controls’) consisted of afebrile intubated 
postoperative open heart surgery patients and patients with intracerebral hemorrhage, 
ischemic cerebrovascular accident or traumatic brain injury without signs of systemic 
inflammation.
Patients were included once norepinephrine infusion was started. Prior to the conduct of this 
study, the local Medical Ethics Committee waived the need for a written informed consent, 
because of the non-invasive nature of the NO-determinations in exhaled air and absence of 
interference with routine clinical care. Patients or family members were informed about the 
study and the acquisition of supplementary plasma. 
Data collection and measurements 
At baseline (start of norepinephrine infusion), day 1, day 3 (±1 day) and day 5 (±1 day) 
clinical data, blood and exhaled air were collected. The average norepinephrine infusion 
rate, mechanical ventilation parameters and the ratio of the partial pressure of arterial 
oxygen to the fraction of inspired oxygen (PaO2/FiO2) were recorded at the moment of 
collection of exhaled air. The Acute Physiology and Chronic Health Evaluation (APACHE)-II 
and the Simplified Acute Physiologic Score-II (SAPS-II) score and was measured the first 24 
hours following ICU admission. In-hospital and 28-day mortality data were collected from 
the electronic patients file.
NO-measurement
A sampling catheter was placed through the sucking opening in the swivel. After a normal 
inspiration with NO-free air the catheter was positioned into the endotracheal tube and the 
expiratory volume was collected into 500 mL NO-impermeable aluminum-foil bags (Mylar 
balloon, ABC ballonnen, Zeist, The Netherlands). NO-concentrations were determined within 
24 hours off-line, using a Quantum Cascade Laser (QCL)-based sensor [16, 17]. Briefly, a QCL 
emits light in 5.2 µm wavelength region where NO exhibits specific absorption features. The 
laser light is sent through an absorption cell where it interacts with the NO molecules over a 
distance of 76 m. The absorbed light is then directly measured with a photodetector, being 
proportional to the concentration of NO in the breath sample. The system has a detection 
limit of 0.5 ppbv (parts per billion, 1:109) within 1 second, it does not require any short-term 
maintenance, and shows a very good agreement with the commercial chemiluminescence 
NO analyzer [17]. Before measurements, the system was calibrated with a reference mixture 
of 100±3 ppbv of NO in N2 (VSL-Dutch Metrology Institute, Delft, the Netherlands). Using this 
protocol, previous experiments showed NO concentrations in the Mylar bags to be stable 
during 30 hours. The measurements were performed at constant laboratory temperature of 
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21ºC. As described, patients were ventilated with NO-free air. Moreover, because sampling 
of exhaled air took place in a closed circuit, influence of ambient NO was negligible.
Blood samples
Blood was collected into 5 mL EDTA containing tubes and immediately placed on ice. Plasma 
was obtained by centrifugation of the blood at 4o C with 2000 rpm for 15 minutes after which 
the plasma was frozen at -80oC until measurements took place. The stable NO metabolites 
nitrite and nitrate (together NOx) were determined using a commercial assay (R&D Systems, 
Minneapolis, MN) using the Griess reaction with a lower limit of detection of 0.156 µmol/L. 
Prior to the analysis the samples were ultrafiltrated using 10,000 molecular weight cutoff 
filters (Merck Millipore, Billerica, USA). Interleukin (IL)-6 concentrations were measured 
using a commercial ELISA (Sanquin, Amsterdam, the Netherlands) with a minimal detection 
level of 1.56 pg/mL.
Statistical analysis
Patient characteristics are expressed as percentages, medians and interquartile ranges 
(IQR) and were compared by the Kruskall-Wallis test or the Fisher’s exact test. Spearman’s 
correlation coefficient was used for determination of a relationship between variables. 
For the other analyses the continuous outcome variables exhibiting a skewed distribution 
were transformed, using natural logarithms. To compare continuous variables between 
the patients with sepsis and the non-inflamed controls One-way ANOVA with Bonferroni’s 
post hoc test was used. Multilevel linear models were used to assess the differences in 
geometric means of the variable of interest (dependent variable) between the patients with 
pneumonia and other infections and the change in time. The individual patient was used 
as the contextual variable allowing the intercept to vary. An initial model was constructed 
Figure 1. Differences of exhaled NO (A), NOx (B)  and IL-6 (C) concentrations between the patients with respiratory 
sepsis, non-respiratory sepsis and non-inflamed controls as assessed by one-way ANOVA using the Ln-transformed 
data. The P-value for this analysis is depicted above the arrow. The other bars above the figures represents the 
comparisons between the other groups.
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with time and group and the interaction between these two as independent variables. The 
analysis was repeated without the interaction term if its effect was not significant. 
For all tests, a two sided P<0.05 was considered significant. Data were analyzed using SPPS 
version 20.0 (IBM, Armonk, NY)  and Graph Pad Prism 5 (GraphPad Software, La Jolla, CA).
RESULTS
20 septic patients and 18 intubated patients as ‘non-inflamed’ controls were included in 
the study. Two patients with both a pulmonary and another focus for the septic shock were 
classified into the pneumonia group. Patient characteristics of the patients with septic 
shock are displayed in Table 1. In the pneumonia group (n=8), Haemophilus influenzae 
(2 patients), Streptococcus pneumoniae (1 patient), Staphylococcus aureus, Morganella 
morganii and Pseudomonas aeruginosa (1 patient), Escherichia coli, Morganella morganii 
and Pseudomonas aeruginosa (1 patient), Klebsiella pneumoniae, Citrobacter braakii and 
Proteus mirabilis (1 patient) were the causative agents. Two patients had culture negative 
pneumonia. In the non-respiratory sepsis group (n=12), 8 patients had an abdominal 
focus (no cultures taken (4 patients, all faecal peritonitis); Enterococcus faecalis/faecium, 
Citrobacter werkmanii and Candida tropicalis  (1 patient); Enterococcus faecium (1 patient); 
Enterococcus species, Lactobacillus species and Bacteroides fragilis (1 patient); Acinetobacter 
lwofii, Enterococcus species and Streptococcus viridians (1 patient)) , 2 patients an urological 
infection (Escherichia coli (1 patient)); Mycobacterium avium and Mycoplasma hominis (1 
Figure 2. Temporal changes for the geometric means of exhaled NO (a) and NOx (b) in the group with respiratory 
sepsis and non-respiratory sepsis. Error bars represent 95% confidence intervals for the geometric means. The 
number of patient data available for the analysis per time point are displayed below the x-axis (respiratory sepsis/
non-respiratory sepsis). * P-value for the comparison between the two groups. † P-value for the change in time.
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Table 1. Patient characteristics.
Patient characteristics Respiratory sepsis
(n=8)
Non-respiratory 
sepsis
(n=12)
Non-inflamed 
controls
(n=18)
Age, yrs [median (IQR)] 69 (49-77) 58 (47-71) 58 (42-72)
Sex [n (% male)] 5 (63) 5 (42) 7 (39)
Length of ICU stay, days [median (IQR)] 13 (17-22)a 9 (3-18) 1 (1-6)a,d
APACHEII [median (IQR)] 26 (24-28) 22 (16-29) 18 (15-22)d
SAPS [median (IQR)] 67 (56-77) 50 (37-69) 35 (27-45)c
Norepinephrin dose, µg/kg/min 
[median (IQR)]
0.52 (0.28-1.08) 0.22 (0.13-0.50) 0.00 (0.00-0.03)c
Corticosteroid administration [n (%)] 6 (75) 6 (50) 2 (11)c
Antibiotic treatment [n (%)] 8 (100) 12 (100) 18 (0)c
28-day mortality rate [n (%)] 2 (25) 2 (18)a 3 (20)b
In-hospital mortality rate [n (%)] 3 (43)a 5 (42) 3 (20)b
Abbreviations: n, number, IQR, interquartile range, ICU, intensive care unit, APACHE, Acute Physiologic and Chronic 
Health Evaluation, SAPS, Simplified Acute Physiologic Score.
amissing data for 1 patient.
bmissing data for 3 patients.
cP< 0.05 between non-inflamed controls and both septic groups.
dP<0.05 between non-inflamed controls and respiratory sepsis group.
patient)), 1 patient a catheter-related bloodstream infection (culture negative) and 1 patient 
a necrotizing fasciitis (Pseudomonas aeruginosa). 
At baseline, the non-inflamed control patients had significantly lower IL-6 and NOx 
concentrations compared to the septic patients with pneumonia or non-respiratory 
infections. Exhaled NO was significantly higher in the pneumonia group compared to 
controls, while the difference in exhaled NO between patients with pneumonia and the 
other patients with septic shock did not reach statistical significance (Figure 1). 
Figure 2 shows the change in time of exhaled NO and NOx for both septic groups. One 
patient in each group died during the first day (exhaled NO 2.8 ppbv (respiratory sepsis) and 
4.3 ppbv (non-respiratory sepsis)). In time, the number of available data declined, because 
improvement in clinical condition resulted in extubation. As there were no significant 
interactions between time and the other variables in the linear mixed model analysis, the 
final model contained only time and the variable of interest as dependent variable. Exhaled 
NO at the different time points was higher in the respiratory sepsis patients than in the non-
respiratory sepsis patients (P=0.05) and for both groups there was a significant decline in 
time (P=0.04). Circulating (geometric) mean NOx concentrations were comparable between 
the two septic groups: 52 (95% CI 33-82), 66 (95% CI 32-134), 41 (95% CI 17-95) and 35 (95% 
CI 15-78)µmol/l in the respiratory sepsis group versus 36 (95% CI 29-44), 45 (95% CI 31-66), 
40 (15-101) and 32 (95% CI 23-46) µmol/l in the non-respiratory sepsis group (P=0.35), at day 
0, 1, 3 and 5, respectively. Concentrations peaked at day 1 followed by a significant decline 
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in the respiratory sepsis group as well as in the non-respiratory sepsis group, (P=0.02). There 
was no correlation between circulating NOx and exhaled NO in both the respiratory sepsis 
group (rs=0.2, P=0.3) as well as in the non-respiratory sepsis group (rs=0.2, P=0.4). 
Exhaled NO did not correlate with markers of disease severity or inflammation, neither in 
the patients with pneumonia (correlation between exhaled NO and norepinephrine infusion 
rate rs=0,14, P=0.5; IL-6 rs=0,17, P=0.4; PaO2/FiO2-ratio rs=0,08, P=0.7; and APACHE-II score 
rs=0.2, P=0.7), nor in the group of patients with non-respiratory sepsis (correlation between 
exhaled NO and norepinephrine infusion rate rs=-0,02, P=0.5; IL-6 rs=0.09, p=0.7; PaO2/FiO2-
ratio rs=0.16, P=0.5 and APACHE-II score rs=0,54, P=0.13). 
DISCUSSION
The are several important findings of this study. Firstly, we found that compared to septic 
shock due to non-pulmonary infections, respiratory sepsis is associated with higher 
excretion of NO. Secondly, we report that exhaled NO decreases in time and exhaled NO 
is not correlated with markers of disease severity or inflammation. Finally, exhaled NO 
measured shortly after intubation in the ‘non-inflamed’ group consisting of ventilated 
patients following cardiac operation or a neurological insult was similar to exhaled NO in 
non-respiratory septic patients, indicating that a pulmonary infection and not pulmonary 
clearance of systemic NO-production is the reason of an increase in exhaled NO in septic 
shock patients
.
Most of earlier studies on exhaled NO focused on the assessment of airway inflammation 
in asthmatic patients [9]. In inflammatory lung disease iNOS is localized in bronchial and 
alveolar epithelial cells and alveolar macrophages [18, 19]. Although several studies 
support the positive relationship between pulmonary inflammation and exhaled NO during 
inflammatory conditions such as acute lung injury in sepsis [2, 20, 21], idiopathic pneumonia 
[22] and acute rejection of lung transplantation [23], this relationship is not clear cut. Animal 
models of acute lung injury showed decreased pulmonary NO excretion due to oxidative 
stress related NO depletion [24, 25]. In humans, exhaled NO remained unchanged few 
hours after cardiopulmonary bypass (CPB) as compared with the levels before CPB [14, 26]. 
Others found reduced NO levels following CPB [27, 28]. The majority of patients undergoing 
lung transplantation had low exhaled NO before and after reperfusion [29]. These studies 
therefore seem to indicate that lung injury in the clinical setting may also be associated with 
reduced levels of exhaled NO.
In the few previous studies on exhaled NO in patients with pneumonia both elevated levels 
of exhaled NO [13, 30] and decreased or similar concentrations as in control subjects were 
reported [31, 32]. The present study shows that pneumonia leads to increased pulmonary 
production and excretion of NO in most patients, although on individual level exhaled NO did 
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not discriminate between sepsis of pulmonary or non-pulmonary origin. Since also the non-
respiratory septic patients needed ventilatory support, differences in acute lung injury in 
these patients may account for the observed variation in exhaled NO
. 
However, we observed 
no relationship between exhaled NO and the extent of lung injury as assessed by PaO2/
FiO2. The latter corroborates previous findings of the absence of a correlation between the 
severity of lung injury and exhaled NO [13, 33]. This apparently paradoxical observation can 
be explained by the complex biology of NO production and consumption. After synthesis, NO 
can react with other molecules as oxygen, superoxide, transition metals, nitrogen and sulfur, 
preventing it to stay in measurable form [34]. As such, the actual NO concentration reflects 
the balance between the production and consumption, the latter being influenced strongly 
during the oxidative stress in acute lung injury [35]. To gain more insight into the influence 
of oxidative stress on exhaled NO, measurement of other substances, like 8-isoprostane, 
a reliable marker of oxidative stress, in exhaled breath condensate would be useful [36, 
37]. Furthermore, a decrease in regional pulmonary blood flow may significantly increase 
exhaled NO, as it prevents the scavenging of NO by hemoglobin [38]. Alveolar hypoxia-
induced vasoconstriction may play a role in alveolar consolidation and mechanical factors 
as the absence or presence of an open airway influence the passage of NO to the proximal 
airways. Finally, exhaled NO not only reflects increased production and transportation, but 
theoretically a decreased production of NO can play a causative role in the etiology of a 
pulmonary infection [12, 31, 39] and it has been hypothesized that low levels of exhaled NO 
make patients more susceptible for pulmonary tuberculosis [31].  
Comparable to exhaled NO, circulating concentrations of NO metabolites show both high 
inter-individual variability and variation during the days after the septic shock [40, 41]. 
However, the change in time showed different kinetics compared to exhaled NO: an early 
peak at day one was followed by a decline. The different half-life of NO and its metabolites 
and the compartmentalized production of NO by iNOS are likely responsible [13, 42].
As the initial improvement in clinical condition was paralleled by a decline in time of exhaled 
NO, this may suggest a relation between the decrease in underlying pulmonary inflammation 
and clinical improvement for the group as a whole. On individual level however, single 
exhaled NO levels were unable to serve as a surrogate marker of disease severity as shown 
by the absence of correlation between exhaled NO and vasopressor dose, IL-6 and APACHE-
II score. 
There are also several limitations of this study. Firstly, the sample size is limited, and future 
studies are warranted to confirm these findings. Secondly, the method of air sampling 
precluded a standardized flow rate during measurement. Instead, we collected the complete 
volume of air during one exhalation, thus reflecting mean exhaled NO during exhalation. 
In future studies, it would be interesting to perform multiple flow rate measurements to 
fractionate NO from alveolar and bronchial sources [43]. Thirdly, mechanical ventilation 
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itself potentially influences exhaled NO [44, 45]. Due to the observational character of our 
study the standard care including the mechanical ventilation was not changed. Moreover, 
the different ventilator modalities were comparable between the septic groups and we did 
not find a correlation between e.g., the amount of applied positive end-expiratory pressure 
and exhaled NO
.
 Fourthly, several drugs can modulate exhaled NO
. 
We feel confident that 
these factors did not bias the observed differences, because nitroglycerin was not used 
and corticosteroids, potentially decreasing NO-production, were administered to 75 and 
50 percent of the patients with pneumonia and other infections, respectively, and we 
did not observe differences between the patients that did and did not receive steroids. 
Furthermore, NO output and concentrations could have been influenced by norepinephrine 
infusion which causes bronchodilation by activating airway smooth muscle cell β2 receptors. 
However, norepinephrine infusion rate did not differ significantly between both groups. 
Finally, in patients with respiratory sepsis, it would also be worth measuring independent 
markers of airway inflammation and/or oxidative stress including exhaled breath volatile 
compounds  [46, 47] and exhaled breath condensate concentrations of leukotriene B4 [48] 
and metabolites [49, 50].
In conclusion, patients with respiratory septic shock have a higher exhaled NO compared 
to patients with non-respiratory septic shock and non-inflamed ventilated ICU patients. 
Exhaled NO decreases in line with clinical improvement, although individual values do not 
correlate with disease severity or other measures of inflammation. These data indicate that 
the infected lungs are the source of exhaled NO and that exhaled NO is not merely the 
results of pulmonary clearance of systemically produced NO.
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ABSTRACT
Background: Cytokine production assays have been primarily used in research settings 
studying novel immunodeficiencies. We sought to determine the diagnostic value of 
cytokine production assays in patients with recurrent and/or severe infections (IDs) without 
known immunodeficiencies and unclassified non-infectious inflammatory disorders (NIIDs). 
Methods: We retrospectively examined the cytokine production in whole-blood or 
peripheral blood mononuclear cell samples in 157 adult patients. Cytokine production rate 
<5% of that of healthy controls was considered defective. 
Results: While monocyte-derived cytokine production (TNF-α, interleukin (IL)-1β, IL-6) 
was rarely affected, 30% of all included patients had deficient production of interferon-γ 
(IFN-γ), IL-17A or IL-22. Twenty-five percent of the NIID patients displayed a defective 
IFN-γ production, whereas IL-17A production was generally unaffected. In the group of ID 
patients, defective IFN-γ production was found in 19% and 14% of the patients with viral or 
bacterial infections, respectively, and in 38%, 24% and 50% of patients with mycobacterial, 
mucocutaneous and invasive fungal infections, respectively. Defective IL-17A and IL-22 
production was mainly confined to ID patients with mucocutaneous fungal infections. 
Conclusions: Cytokine production assays frequently detect defective Th1 responses in 
patients with mycobacterial or fungal infections, in contrast to patients with respiratory 
tract infections or isolated bacterial infections. Defective IL-17A and IL-22 production 
was primarily found in patients with fungal infections, while monocyte-derived cytokine 
production was unaffected. Thus, lymphocyte-derived cytokine production assays are 
helpful in the diagnostic work-up of patients with recurrent infections and suspected 
immunodeficiencies, and have the potential to reveal immune defects that might guide 
adjunctive immunomodulatory therapy.
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INTRODUCTION
Traditionally, primary immunodeficiencies are thought to be represented by rare 
monogenetic disorders directly affecting immune system development or function leading 
to multiple, recurrent, unusually severe and opportunistic infections in childhood [1, 2]. 
However, in the last decade this relatively rigid description of immune deficiencies has been 
challenged [1, 2]. The increasing understanding of immune responses and the expansion 
of the existing investigative tools enabled the deciphering of the genetic basis of many 
conditions that are accompanied by an increased susceptibility to infections, as well as of 
various non-infectious inflammatory disorders (NIIDs). Nowadays, it is thought that even 
individuals suffering from a single unusual infection could be affected by an immune defect, 
and thus immunodeficiencies should be considered in a wide range of clinical situations [1, 
2]. 
Highly conserved molecular structures of microorganisms, called pathogen associated 
molecular patterns (PAMPs) [3], are recognized by pattern-recognition receptors (PRR). 
Defects of PRR and the subsequent signaling pathway are usually accompanied by a 
diminished production of pro-inflammatory cytokines, and they represent a paradigm shift 
in the field of primary immunodeficiencies [4, 5]. Similarly, various NIIDs are due to the 
loss of regulation of cytokine production and coined as autoinflammatory disorders [6]. 
In addition to PRR defects, specific immunodeficiencies have been described in patients 
with defective cytokine or cytokine-receptors, such as interleukin (IL)-12/IL-12R/interferon 
(IFN)-γ/IFN-γR defects associated with mycobacterial and Salmonella infections [7, 8], or IL-
17F/IL-17R deficiencies, which are associated with fungal infections [9].
Until now, assessment of the integrity of cytokine production in stimulated peripheral-
blood mononuclear cells (PBMCs) has been mainly used to examine patients with novel 
primary immunodeficiencies [10, 11]. However, cytokine production defects may be much 
more common in patients with recurrent infectious diseases (IDs) [5] or suspected auto-
inflammatory NIIDs [6], and assessment of cytokine production may have diagnostic value 
in these patients. In the present study we review cytokine production in a large series of 
patients suffering either from a recurrent infection, an unusually severe course of infection, 
an opportunistic infection, or a NIID, who presented at our tertiary center for infectious 
diseases, immunodeficiencies and autoinflammation.
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CASE ILLUSTRATION
A 28-year-old male, known with diabetes mellitus type I, hypothyroidism, and systemic 
lupus erythematosus treated with hydroxychloroquine, had suffered from five episodes of 
pneumonia since the age of 25. Twice, Streptococcus pneumoniae was isolated. One culture-
negative pneumonia was complicated by pancytopenia and autoimmune hemolytic anemia. 
Furthermore, he had recurrent oropharyngeal candidiasis and persistent dermatomycosis 
of the right foot. These manifestations were compatible with a large spectrum of diseases, 
with chronic mucocutaneous candidiasis (CMC) among them. However, Sanger sequencing 
of exomes 6 to 11 of STAT1, a region in which earlier studies identified mutations [10, 12], 
revealed no abnormalities. Therefore, the patient was referred for further diagnostic 
analysis. PBMC stimulation showed normal tumor necrosis factor alpha (TNF-α), IL-1β, and 
IL-6 production when stimulated with LPS and Candida albicans, making it improbable that 
deficiencies of dectin-1, caspase recruitment domain-containing protein (CARD) 9 mutations, 
interleukin-1 receptor-associated kinase (IRAK) 4, and myeloid differentiation primary 
response 88 (MyD88) deficiencies were the cause. However, the production rates of IFN-γ, 
IL-17A and IL-22 was <10%, <5% and <5% compared to that of healthy controls, respectively, 
supporting the hypothesized diagnosis of CMC. Further extended genetic analysis by whole 
exome sequencing showed a novel missense mutation, replacing aspartic acid by valine at 
position 24 (D24V), in exome 3 of STAT1 with probably with similar effects on STAT1 function 
as previously described for the gain-of-function mutations in exon 6 to 11.  
PATIENTS AND METHODS
Patients
All consecutive patients with either a recurrent infection, an infection of unusual etiology 
or severity, and so far unclassified patients suspected for NIID hospitalized or visiting the 
outpatient clinic of the Department of Internal Medicine, Radboud University Nijmegen 
Medical Center between 2001 and April 2013, were included in the study. Patients with 
immunosuppressive drugs, HIV infection, hematological malignancies, or known primary 
immunodeficiencies were excluded. 
Classification and data analysis
The group of ID patients was classified based on the clinical presentation into: (A) ear-nose-
throat or airway infections, (B) pyogenic infections, or (C) opportunistic infections (mainly 
caused by intracellular bacteria, viruses and fungi) [13] (Figure 1). In addition, ID patients 
were classified based on the main causative microorganism: (a) viral, (b) bacterial, (c) 
mycobacterial or (d) fungal infections, the latter further separated into (d1) mucocutaneous 
fungal infections and (d2) invasive fungal infections (Figure 2).
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Cytokine production assays
Whole-blood (WB) stimulation assays were performed from 2001 until 2008. Peripheral 
blood mononuclear cells (PBMCs) stimulation assays were done from 2008 to 2013.
For the WB stimulation assays, venous blood was collected in lithium-heparin tubes, diluted 
to a final concentration of 1/5 in RPMI 1640 (Dutch modified; Gibco, Invitrogen, Breda, the 
Netherlands), and plated out at 1 mL/well in 24-well tissue culture plates. Stimulation was 
performed by adding 100 μL culture medium (negative control), and the following stimuli 
(final concentrations in parantheses): LPS derived from Salmonella typhimurium (10 ng/mL), 
S. typhimurium bacteria (heat-killed (HK), 107 microorganisms (m.o)/mL), Staphylocococcus 
aureus (HK, 107 m.o./mL), Aspergillus fumigatus conidia (HK, 107 m.o./mL) and C. albicans 
conidia (HK, 107 m.o./mL). Mycobacterium tuberculosis sonicate (HK, 1 µg/mL) or Poly I:C 
(50 µg/ml; Invivogen, San Diego, CA) were also included in case of a mycobacterial or a viral 
infection, respectively. Microorganisms were killed by heating them for 1 hour at 95°C. After 
incubation for 24h or 48h at 37°C, supernatants were obtained by centrifugation and stored 
at −20°C until IL-6, IL-1β, TNF-α (all 24 h) and IFN-γ (48 h) measurements were performed. 
The experiments were done in duplicate. 
For the PBMC-stimulation assay, venous blood samples were collected into EDTA tubes. 
Figure 1. Flow chart of the 157 patient in whom cytokine production assays were performed. Abbreviations: WB, 
whole-blood stimulation. PBMC, peripheral blood mononuclear cell stimulation, A, recurrent respiratory tract 
infection, B, pyogenic infections, C, opportunistic infections.
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PBMCs were isolated according to standard protocols, with minor modifications [14]. The 
PBMC fraction was obtained by density centrifugation of blood diluted 1:1 in phosphate-
buffered saline (PBS) over Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). Cells 
were washed three times in PBS and resuspended in RPMI 1640 (Dutch modified; Gibco, 
Invitrogen, Breda, the Netherlands) supplemented with 50 mg/L gentamicin, 2 mM 
L-glutamine, and 1 mM pyruvate. Cells were counted in a Coulter Counter Z (Beckman 
Coulter, Mijdrecht, the Netherlands) and adjusted to 5 × 106 cells/mL. Mononuclear cells 
(5 × 105) in a 100μL volume were added to round-bottom 96-well plates (Greiner, Alphen 
a/d Rijn, the Netherlands) and incubated with either 100μL of culture medium (negative 
control) or one of the stimuli for 24 h (TNF-α, IL-1β and IL-6), 48 h (IFN-γ) and/or 7 days (IL-
17A and IL-22). Monocyte-derived cytokine production was tested with LPS derived from 
Escherichia coli, Pam3Cys, muramyl dipeptide and β-glucan. Both monocyte-derived and 
lymphocyte-derived cytokine production were tested with HK S. aureus (106 or 107 m.o./
mL) and HK C. albicans conidia (105 or 106 m.o./mL). Sonicated M. tuberculosis (1 or 10 μg/
mL), HK M. abscessus (105 m.o./mL), HK M. fortuitum (105 m.o./mL) or Poly I:C (5 or 50 μg/
mL; Invivogen, San Diego, CA) was included if the patients suffered from a mycobacterial 
or viral infection, respectively. αCD3/αCD28 (2,5*106 beads/5*106 PBMC; Miltenyi Biotec, 
Figure 2. Proportion of patients with infectious diseases (n=117), stratified according to microbial etiology [viral 
(a, n=16), bacterial (b, n=36), mycobacterial (c, n=16), mucocutaneous fungal (d1, n=33), invasive fungal (d2, 
n=16)] with low lymphocyte-derived cytokine production either as assessed by whole-blood or peripheral blood 
mononuclear cell stimulation tests. The number (%) of patients with each kind of infection and a deficient cytokine 
production are shown on the right for each category. P-values are shown for the comparison between group d2 and 
the other groups.
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Bergisch Gladbach, Germany) was used in lymphocyte-derived cytokine production assays. 
Microorganisms were killed by heating them for 1 hour at 95°C. C. albicans and S. aureus, 
were chosen because of their potency to induce IFN-γ, since E. coli LPS is a poor inducer 
of IFN-γ. C. albicans and S. aureus were well suited as strong stimuli for IL-17A and IL-22 
release (Figure S1). 10% human pooled serum was added when PBMCs were incubated 
during 7 days. After incubation the supernatants were stored at −20 °C until assay. The 
experiments were performed in duplicate. 
Until 2006, TNF-α was measured using an in-house radioimmunoassay with a lower limit 
of detection of 15 pg/mL. Thereafter, TNF-α was measured with a commercial ELISA kit 
from R&D Systems (Minneapolis, MN), which has a lower detection limit of 78 pg/mL. 
IL-6 and IFN-γ concentrations were assessed using commercial ELISA kits from Sanquin 
(Amsterdam, the Netherlands) with a lower detection limit of 15 pg/mL and 8 pg/mL, 
respectively. IL-1β, IL-17A, and IL-22 were measured using commercial ELISA kits from R&D 
Systems (Minneapolis, MN) with 39 pg/mL, 16-78 pg/mL and 78-155 pg/mL as lower limits 
of detection, respectively. 
Cytokine production, i.e. the concentration in the stimulated sample, was compared 
between patients and healthy volunteers (anonymous blood donors, who gave their written 
informed consent for the use of their blood for scientific purposes as approved by the 
ethics Committee of Radboud university medical center.) tested the same day in the same 
run. In case of more than one healthy control, values were pooled and averaged. Cytokine 
production was compared with that of healthy volunteers, tested in the same experiment. 
To calculate the proportion of patients with a deficient production, cytokine concentrations 
of less than 5%, 10% and 20% compared to healthy volunteers (i.e. a ratio patient/control 
<0.05, <0.10 and <0.20, respectively) were used. For the main analysis, we defined a cytokine 
production to be defective when the production upon exposure to at least one stimulus 
was less than 5% as compared to healthy controls. This stringent threshold was chosen 
because healthy controls rarely had cytokine concentrations less than the 5th percentile of 
the concentrations found in the whole population (patients + controls) (Table S1 and Figure 
S2) and the 5% cutoff value was associated with most concordant test results in patients 
who were tested twice (Table S2). If experiments were repeated, only concordant results 
were considered to represent a defective response.
Statistical analysis
The main outcome measures of the study are descriptive. Proportions of affected patients 
among the different categories were identified using cross tables. To test for the relationship 
between these categorical variables the Chi-square test and in case of less than 5 expected 
counts Fisher’s exact test was performed. The Mann-Whitney U test or the Kruskal-Wallis with 
Dunn’s post test were used to compare (absolute) cytokine concentrations between two or 
more independent groups, respectively. A P-value <0.05 was considered statistically significant.
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RESULTS
Patient characteristics
In total 157 patients were included: 33 underwent WB stimulation and 124 underwent 
PBMC stimulation. One hundred forty-six patients were ambulant, and 11 were hospitalized 
at the moment of sampling. Nine patients were receiving anti-mycobacterial treatment 
while the tests were performed. Test indications are presented in Figure 1. In all tested 
patients the production of TNF-α, IL-1β and IL-6 was measured. The production of IFN-γ, IL-
17A and IL-22 was tested in a selection of patients (Figure 1) due to new developments and 
insights during the implementation of the tests (IL-22 assessment became available only in 
the last years of the study). 
Production of TNF-α, IL-1β and IL-6 in the WB and PBMC assay
Only 4 of the 157 tested patients had decreased production of <5% compared to that 
of the controls of one of the monocyte-derived cytokines, TNF-α, IL-1β  or IL-6 (Table 
1). Four patients with an infection had defective TNF-α or IL-6 production. Of the three 
patients with defective TNF-α production, one had disseminated cryptococcosis, one had 
tuberculous meningitis and one had recurrent pneumococcal meningitis with cerebrospinal 
fluid leakage. The patient with defective IL-6 production and recurrent herpes infections 
also displayed low IFN-γ production (<10%) upon stimulation with the TLR3 ligand poly I:C. 
Table 1. Patients with defective monocyte-derived cytokine production.
Age Sex Group Clinical picture Cytokine Stimulia Interval 
diagnosis-test
Underlying defect
34 M Infection Disseminated 
cryptococcosis
TNF-α 3 1 week n.p.
42 F Infection Recurrent herpes 
simplex virus-2 
meningitis
IL-6 1 3 years n.p.
64 M Infection Recurrent pneumococcal 
meningitis
TNF-α 1 4 months Cerebrospinal fluid 
leakage
42 M Infection Neurological 
deterioration after
tuberculous meningitis
TNF-α 3 13 months n.p.
Abbrevations: M, male, NIID, non-infectious inflammatory disorder, n.p., not performed, F, female
aNumber of stimuli  that resulted in a deficient response.
Except for the patients with disseminated cryptococcosis, cytokine production was tested 
after the resolution of infection, and showed normal results, precluding a defective result 
due to down-regulated cytokine production during acute infection [15].
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Production of IFN-γ, IL-17A and IL-22 in the cytokine production assays
Overall, 56/157 (36%) of the measurements indicated a production rate of <5% compared to 
healthy controls of at least one of the three cytokines, corresponding to 47 (30%) individual 
patients (32% ID; 25% NIID) (Figure 1).
Production of IFN-γ in the WB assay
IFN-γ production was impaired in 13 patients of the 33 tested patients with the WB assay, 
9 of whom had an ID and 4 patients who had a NIDD (Table 2). For patients with an ID, 
decreased IFN-γ production was found only in those with a pyogenic or opportunistic 
infection (Figure 1). 
Production of IFN-γ, IL-17A and IL-22 in the PBMC assay
The results of the assays testing the production of T-lymphocyte derived cytokines IFN-γ, 
IL-17A and IL-22 are summarized in Figure 1. Overall, 43 (35%) of the tests were indicative 
of deficient production, corresponding with 35 (28%) individual patients (34% of those 
with an ID and 19% of those with a NIID). (Table 3, 4 and 5). When patients were grouped 
according to the microbial etiology, the assay result was most often abnormal in patients 
with mycobacterial and fungal infections (Table 6 and Figure 2).  
Diminished IFN-γ production was found in 21 ID patients and 6 NIDD patients (Figure 1). 
Interestingly, three-quarters of the ID patients with low IFN-γ production were patients 
with mycobacterial and fungal infections (Table 3). One patient with progressive multifocal 
leukencephalopathy and two with recurrent herpes virus infections had a low IFN-γ 
production after stimulation with Poly I:C. Among the 6 NIID patients with a defective IFN-γ 
release, two had hidradenitis suppurativa and one had sterile subareolar abscesses (Zuska 
disease) [16], disorders thought to have a shared pathogenesis. 
Impaired IL-17A production was observed in 6 ID-patients, all suffering from fungal infection, 
five of which were refractory mucocutaneous infections and one was an  invasive infection 
(Table 4 and Table 6). 
Deficient IL-22 production was also predominantly observed in ID patients with 
mucocutaneous infections, mainly of fungal etiology (Table 5). The one patient with NIID 
and a defective IL-22 release had sterile subareolar abscesses.
A final diagnosis of hyper IgE syndrome (HIES) was reached in 10 patients, five of whom had 
a STAT3 mutation. Six patients with CMC were included (STAT1 mutation were found in four 
of them). Deficient IFN-γ production (WB and PBMC combined, C. albicans and S. aureus as 
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Table 6. Abnormal tests of patients with infectious diseases, stratified according to microbial etiology, type of assay 
and cytokine.
Infection type
WB stimulation 
(n=25)
PBMC stimulation 
(n=92)
Total Low Total Low
IFN-γ IFN-γ IL-17 IL-22
Viral 0 0 16 3 0 0
Bacterial 12 2 24 3 0 1
Mycobacterial 3 1 13 5 0 1
Fungal, mucocutaneous 2 0 31 8 5 5
Fungal, invasive 8 6 8 2 1 2
Abbreviations: WB, whole blood, n, number, PBMC, peripheral blood mononuclear cells.
stimuli) was a relatively sensitive marker for HIES: 60% of the patients with HIES produced 
less than 5% compared to healthy controls and 80% less than 10% (Figure S3). All CMC 
patients displayed a deficient production of one of the lymphocyte-derived cytokines upon 
stimulation with C. albicans and S. aureus: IFN-γ was defective in 67%, IL-17A in 67% and 
IL-22 in 75% of the patients (Figure S3).
Figure 3 shows the absolute cytokine concentrations of the abnormal tests for controls 
versus patients, NIID versus ID patients and the IFN-γ concentrations in patients with 
mycobacterial, bacterial and fungal infections. 
IFN-γ production in patients with mycobacterial infections
PBMCs of healthy individuals mount an IFN-γ response when exposed to M. tuberculosis 
sonicate just by previous exposure or BCG vaccination [17]. Thus, inherent to the reference 
standard chosen (i.e. <5% of that of healthy controls), a low IFN-γ response of non-BCG-
vaccinated ID-patients to mycobacterial stimuli, as was found in 6 ID-patients, may not 
be interpreted as defective. Still, 6 other ID-patients with mycobacterial infection had a 
deficient IFN-γ production to non-mycobacterial stimuli. 
Figure 3. Absolute cytokine concentrations for the abnormal tests (i.e. production <5% of controls) of patients (P) 
versus controls (C) (panel A), non-infectious inflammatory diseases (N) versus inflammatory disorders (I) (panel B) 
and mycobacterial versus, bacterial and fungal infections (panel C). N.s. and n.a. denote non significant and not 
applicable, respectively.
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Impact of cutoff values
Figure 4 illustrates the impact of our stringent cutoff values (<5%) on the diagnostic 
performance for the patients with fungal infections. As also shown in Supplementary 
Table 3 a higher cutoff value would have identified more patients with low lymphocyte-
derived cytokine production, except for patients with viral infections and mycobacterial 
infections. The increase (44 to 63%) in patients with mycobacterial infections was not 
statistically significant, probably due to the small sample size. Across all three reference 
values mycobacterial and fungal infections were predominantly associated with positive 
test results. For NIID, with the 5% as reference category (25% (10/40)), the use of 10% and 
20% as cutoff value increased the proportion of affected patients to 45% (18/40, P=0.06) 
and 50% (20/40, P=0.02)
DISCUSSION
Using functional investigations of ex-vivo cytokine production, we demonstrate defective 
cytokine production in one-third of adult patients referred to a tertiary center for infectious 
diseases, immunodeficiencies and autoinflammation because of recurrent, severe or 
opportunistic infections or the suspicion of a NIID. 
It is currently unclear to what extent the defects found represent genetic or acquired 
disorders. Only in a few patients there were family members with similar ailments, making 
the search for a genetic defect difficult. However, with the advent of powerful genetic 
techniques like next generation sequencing, finding genetic defects guided by functional 
Figure 4. Ratio of IFN-γ, IL-17A and IL-22 production between patients and healthy volunteers for tests of patients 
with fungal infections. Test results considered deficient, i.e. production <5% of controls (ratio <0.05) are grouped 
as “L”. Results considered as normal (ratio >0.05) are grouped as “N”. The horizontal dashed line indicates the used 
reference standard (ratio = 0.05).
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findings is more into reach. In fact, such an approach was used to detect a STAT1 gene 
mutation as the cause of autosomal dominant CMC [10].
In our study, deficient production of lymphocyte-derived cytokines was frequently found, 
especially in patients with opportunistic infections of viral, mycobacterial or fungal etiology 
reveal significant abnormalities. Thus, these groups of adult patients should represent the 
target of investigation of cytokine production defects. 
The defective IFN-γ production observed in many of the patients with mycobacterial 
infections (mainly non-tuberculous mycobacteria (NTM)) reflects the key role of IFN-γ in 
macrophage activation for mycobacterial killing [7]. It is known that patients with mutations 
in the IL-12/IFN-γ signaling pathway are vulnerable to disseminated infections with mildly 
virulent mycobacteria. In contrast to our patients, the patients with these defects are often 
identified at young age [7, 8], arguing for more subtle defects in our adult patients. Although 
it has been reported that NTM infection itself may suppress IFN-γ responses [18], defective 
cytokine release was also found in patients who had recovered from their NTM infection. 
In 7 patients with invasive fungal infections we found defective IFN-γ production. This 
underscores the important role of the Th1-response, which in addition to the defense by 
phagocytic cells, activates the host resistance to fungi [19].
The importance of Th17-responses for mucosal antifungal immunity [9, 10, 20-22] was 
confirmed by the identification of IL-17A/IL-22 defects in our patients with mucosal fungal 
infections. In our series, a number of patients were included who turned out to suffer from 
HIES. These patients did not present with the typical features and/or an informative family 
history. Based on the functional analysis that yielded defective IFN-γ response to C. albicans 
and S. aureus, genetic analysis was performed. The case of the new STAT1 variant also 
illustrates how functional analysis may guide subsequent genetic search.
Remarkably, two patients with an intracranial Aspergillus infection had impaired IL-22 
production, isolated or in combination with IFN-γ and IL-17A deficits. Reportedly, patients 
with HIES and defective Th17 response are at risk for invasive fungal infections [19, 23]. An 
impaired mucosal host defense, as demonstrated by the defective IL-22 or IL-17A production, 
may have led to increased fungal colonization of the nasal cavity and paranasal sinuses, 
impaired epithelial integrity and invasion of the deeper tissues [24, 25]. 
Besides the possibility to explore underlying immunodeficiencies, it is tempting to speculate 
that a defective IFN-γ functional test may guide the use of adjunctive immunomodulatory 
therapy such as recombinant IFN-γ therapy [26]. Therapy with IFN-γ has been used 
successfully for the prevention and treatment of fungal infections (especially aspergillosis) 
in patients with chronic granulomatous disease [27]. 
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An unexpected finding of the present study was the defective IFN-γ production found in 10 
patients with NIID. Of these patients, 4 had hidradenitis suppurativa or sterile subareolar 
abscesses, in which follicular occlusion is thought to be the initial event in the pathogenesis. 
It is widely acknowledged that Th17 cells play a prominent role in autoimmune and 
autoinflammatory disorders [28]. Recently, it has been shown that the IL-23/Th17 pathway 
is overexpressed in hidradenitis suppurativa [29] and this provides a rationale for the use 
of biologicals interfering with the Th17 pathway, like ustekinumab (anti-IL-12/IL-23) and 
anakinra (IL-1Ra) [30, 31].  Given the known suppressive effect of IFN-γ on the expansion 
of Th17 cells [28], the absence of IFN-γ production in affected skin [32] and circulating 
lymphocytes as found here suggests a role of defective Th1 responses for the overproduction 
of IL-17A. 
With regard to the production of monocyte-derived cytokines we rarely found defects. 
Disorders characterized by defective production of monocyte-derived cytokines, such as 
MyD88 and IRAK-4 deficiency, predispose to recurrent pyogenic bacterial infections during 
childhood [33]. The occurrence of these infections at young age, the severity of these 
infections, and the decrease in susceptibility with increasing age, likely explain the absence 
of these functional phenotypes in our cohort of adult patients.
Obviously, our observational explorative study has also some limitations that should be 
acknowledged. Firstly, our studies are retrospective and were performed over many years 
and hence, methodology evolved. In addition as well known from previous surveys, ex-vivo 
cytokine production has a large inter-individual variation [34], hampering the establishment 
of reference values. We compared cytokine production in infected patients with that of 
healthy volunteers tested in the same experiment in order to control for procedural variability 
of the investigations. One limitation of the study regards the fact that in most cases no age- 
and sex-matched controls were available, and blood from anonymous healthy blood donors 
was used. We applied stringent cutoff values (i.e. < 5% of the cytokine production in healthy 
controls) in order to minimize false-positive results. Hence, we may have missed some mild 
defects of cytokine production [35]. We used fixed concentrations of stimulus, but we are 
aware that exposure to stimuli in a dose range could provide extra information. Again we 
may have missed some mild defects as we used relatively high concentrations of ligand. 
Especially, in autoinflammatory disorders, which are characterized by an exaggerated 
immune response to relatively mild stimuli, the use of a dose-response curve provides a 
way to evaluate overproduction. Thirdly, two methods to determine cytokine production 
were used: WB stimulation assay and PBMC stimulation assay. Although the latter method 
is more time-consuming, it allows for an assessment of IL-17A and IL-22 production, in 
addition to that of IFN-γ. Despite differences in cell types and non-cellular components 
between the two methods, we think the results are generalizable, because the correlation 
between these methods is good [34]. Nevertheless, standardization of the methodology in 
the future is crucial, in order to make these tests available for larger numbers of patients.
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The incorporation of measurements of additional cytokines may improve the identification 
of more immunodeficiencies. For example, assessment of IFN-α, IFN-β and/or IFN-λ may 
be of added value in evaluating the antiviral responses [36]. Circulating leukocytes do not 
necessarily reflect the entire immune status at tissue level [37] and stimulation of non-
hematopoietic cells may reveal an immunodeficiency, while PBMCs are normally responsive 
[36]. 
In conclusion, retrospective analysis of ex-vivo cytokine release assays in over 150 patients 
with recurrent and/or severe infections or NIID revealed functional defects in Th1 and Th17 
responses to be relatively common in patients with mycobacterial, fungal or viral infections 
and patients with NIID. These assays are well suited to detect defects in immune pathways 
relating to different infectious phenotypes. These functional findings may guide genetic 
studies using advanced powerful techniques, thereby establishing a molecular diagnosis. 
In addition the findings may guide adjunctive immunomodulatory therapy. Future studies 
using standardized methodologies to assess cytokine production are warranted to better 
understand the immunologic defects in patients with infections and NIID.
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SUPPLEMENTARY MATERIAL
Table S1. Number of controls and patients with cytokine concentrations below the 5th, 10th and 20th percentile 
of the whole population after stimulation of peripheral blood mononuclear cells (PBMC) with Candida albicans 
(10^5/mL).
IFN-γ (n=113) IL-17A (n=94) IL-22 (n=69)
Percentile Conc 
(pg/
mL)
Control Patient Conc 
(pg/
mL)
Control Patient Conc 
(pg/
mL)
Control Patient
5th 8 0 10 42 2 6 78 0 9
10th 18 2 18 116 4 13 94 0 12
20th 48 10 30 252 8 26 203 3 21
Abbreviations: n, number, conc, concentration.
Table S2. Inter-test agreement for IFN-γ, IL17A and IL-22 production. 
Cutoff
WB PBMC
IFN-γ 
(n=7)
Pa IFN-γ 
(n=24)
Pa IL-17A 
(n=19)
Pa IL-22 
(n=12)
Pa
5% 57% ref 71% ref 100% ref 83% ref
10% 43% 1.0 67% 0.76 79% 0.10 58% 0.37
20% 57% 1.0 67% 0.76 53% 0.001 50% 0.19
Abbreviations: WB, whole blood stimulation, PBMC, peripheral blood mononuclear cell stimulation, n, number, 
ref, reference.
aP-value shown for the comparison between the 5% and 10% cutoff value (middle row) and between the 5% and 
20% cutoff value (last row).
Table S3. Proportion of patients with infectious diseases (n=117), stratified according to microbial etiology, for the 
different cutoff values.
ID Group 5% Pa 10% Pa 20% Pa Pb Pc
Viral 3/16 (19%) 0.06 4/16 (25%) 0.01 4/16 (25%) <0.001 1.0 1.0
Bacterial 6/36 (17%) 0.01 10/36 (28%) 0.005 19/36 (53%) 0.004 0.26 0.001
Mycobacterial 7/16 (44%) 0.72 9/16 (56%) 0.46 10/16 (63%) 0.08 0.48 0.29
Fungal, 
mucocutaneous
13/33 
(39%) 
0.48 15/33 (46%) 0.12 21/33 (64%) 0.03 0.62 0.04
Fungal, invasive 8/16 (50%) ref 11/16 (69%) ref 15/16 (94%) ref 0.28 0.01
aFungal invasive group is the reference (ref) group.
bP-value for the comparison between the proportion of affected patients within one ID group using 5% and 10% 
as cutoff values.
cP-value for the comparison between the proportion of affected patients within one ID group using 5% and 20% 
as cutoff values.
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Figure S1. Production of IFN-γ, IL-17A and IL-22 upon stimulation with LPS, Poly I:C, αCD3/αCD28, heat-killed (HK) 
C. albicans conidia, and HK S. aureus in healthy volunteers in the PBMC stimulation assay. Bars indicate standard 
error of the mean.
Figure S2. IFN-γ, IL-17A and IL-22 production by peripheral blood mononuclear cells from healthy volunteers (C) 
and patients (P) after stimulation with Candida albicans (105/mL).
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Figure S3. IFN-γ (whole blood and PBMC stimulation), IL-17A and IL-22 production in patients (column with P) 
hyper IgE syndrome (panel A-C) and chronic mucocutaneous candidiasis (panel D-F) compared to healthy controls 
(column with C). The ratio of IFN-γ, IL-17A and IL-22 production between patients and healthy volunteers are 
shown in the column with R.
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ABSTRACT
Early and targeted antibiotic treatment of infectious diseases is essential for a favorable 
outcome, but antibiotic overuse should be avoided in order to minimize costs, the risk of 
adverse events, and to decrease the development of antibiotic resistance. Most clinical signs 
and microbiological tests do not provide reliable, rapid, and discriminative information to 
guide antibiotic treatment. However, biomarkers reflecting the host immune response may 
offer an attractive strategy to predict the etiology of an inflammatory process and be helpful 
in decision making. In this review, we discuss the value of inflammatory biomarkers in adult 
patients admitted to the hospital with suspected systemic acute infections and focus on 
the following four clinically relevant questions: (1) Is the patient suffering from an infection 
or a non-infectious inflammatory disorder? (2) Does this patient have a bacterial or viral 
infection? (3) Does the patient have a bacterial or a fungal infection? (4) Is a specific agent 
responsible for the infection?
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INTRODUCTION
Early knowledge of the etiology of inflammatory disorders is essential, as it facilitates effective, 
timely and targeted treatment [1-3]. On the other hand, unnecessary antibiotic treatment 
of viral illnesses or non-infectious inflammatory disorders (NIID) leads to increased costs, 
adverse drug reactions and antibiotic resistance. Unfortunately, the discriminative value 
of clinical findings is usually insufficient [4]. Likewise, many microbiological tests, such as 
cultures, serology and PCR each have their own limitations (difficulty to obtain a relevant 
biological specimen, low sensitivity, high costs and long turnaround times), which restrict 
their impact on early decision making. Biomarkers that reflect the host response may offer a 
solution to this problem. In this review, we summarize how circulating biomarkers reflecting 
the host immune response may aid in the differential diagnosis of adult patients admitted 
to the hospital with suspected systemic acute infections. We focus on four clinically relevant 
questions. (1) Is the patient suffering from an infection or a NIID? (2) Is there an active viral 
or a bacterial infection that causes the symptoms? (3) Does the patient have a bacterial or a 
fungal infection? (4) Is a specific agent responsible for the infection? 
This review itself does not contain a meta-analysis, but has rather a descriptive nature 
including the reporting of the sensitivity, specificity and the area under the receiver operating 
characteristics curve (AUROC). The AUROC is obtained by plotting sensitivity against 
1-specificity for the different values and is a general measure of diagnostic performance. 
A value of 0.50 indicates no discriminative performance, while an area of 1.0 corresponds 
with perfect discrimination. An AUROC 0.5-0.7 is considered a low diagnostic accuracy, 0.7-
0.9 indicates a moderate diagnostic accuracy, and >0.9  a high accuracy [5, 6].
CELLULAR DIAGNOSTIC BIOMARKERS 
Leukocyte count and differentiation
White blood cell count (WBC) cannot reliably be used for the distinction between infectious 
diseases and NIID, since leukocytosis accompanies many conditions [7]. In addition, 
leukocytosis lacks sensitivity: only half of the patients admitted to the emergency department 
(ED) or intensive care unit (ICU) with an infection had an elevated WBC [8, 9]. A WBC of < 4 x 
109/L proved to be more specific for bacterial infection in the ICU in one study, but was rarely 
encountered (10%) [9]. Also, the role of WBC in the diagnosis of bacterial or viral origin 
is limited, with reported AUROC from 0.66-0.80 in studies with a clinically heterogeneous 
population [10, 11]. Absolute neutrophil count may be a better predictor in a population 
with diverse infectious pathology [10, 11], but its diagnostic accuracy has not been studied 
systematically in patients with a more homogeneous clinical picture, like pneumonia. The 
use of neutrophil-lymphocyte count ratios has not been addressed in relevant studies. 
Likewise, the diagnostic potential of assessing circulating immature granulocytes (‘left shift’) 
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has not been studied extensively. In a prospective study performed in a medical ICU, band 
counts greater than 10% had a relatively low sensitivity of 43% and specificity of 92% for 
the diagnosis of (microbiologically-confirmed) infection [9]. Circulating metamyelocytes, 
myelocytes and promyelocytes (immature granulocytes count) had an AUROC of 0.73-0.86, 
a sensitivity between 58 and 89% and specificity of around 80%, for the distinction between 
sepsis and non-infectious systemic inflammatory response syndrome (SIRS) in the ICU [12, 
13]. Eosinopenia (with cutoffs of 25-50 cells/mm3) as a diagnostic marker of sepsis in the ICU 
has been reported to have a sensitivity of around 80%, specificity between 65-80%, and an 
AUROC of 0.72-0.89 [14, 15]. However, others could not confirm the discriminatory value of 
eosinopenia in this context [16, 17]. 
Leukocyte surface markers
CD64 is a high-affinity immunoglobulin-Fc fragment receptor I (FCγRI), which is only weakly 
expressed on the surface of non-activated neutrophils (nCD64) [18], but is strongly up-
regulated in response to pro-inflammatory cytokines [19]. In a sub-analysis of a recent 
meta-analysis, including only studies in adults at the ED, ICU or hospital wards, nCD64 had 
an AUROC of 0.94, (pooled sensitivity 76%, specificity 87%)  for distinguishing between 
clinically and/or microbiologically confirmed bacterial infections and NIID [20]. A more 
recent study including suspected sepsis patients at the ICU showed a similar AUROC: 0.95 
and a sensitivity of 87% and specificity of 97% [21]. Interestingly, nCD64 has also shown to 
be of value as a marker of infection in patients with rheumatoid arthritis (RA), regardless 
of disease activity, while similar expression levels were observed between bacterial, 
mycobacterial and viral infections [22]. Mokuda et al. confirmed the shortcomings of nCD64 
in discriminating viral from bacterial infection complicating RA [23]. Accordingly, influenza 
A infections also leads to increased nCD64 [24], thus making it less suitable as discriminator 
between a bacterial and viral etiology in respiratory tract infections.
In a small study of RA patients with viral or bacterial complications, CD35 (complement 
receptor 1) expression on neutrophils (nCD35) had an AUROC of 0.83 for the diagnosis of 
bacterial infection. Nuutila et al. included 286 patients < 48 hours after hospitalization for 
suspected infection and classified them on clinical and microbiological grounds as having 
bacterial or viral infections [10]. The single most useful marker was nCD35 with an AUROC 
of 0.90 and a sensitivity of 79% and specificity of 80%. The addition of monocyte FcγRII 
and C5a-receptor expression, and the ratio of neutrophilic and monocytic MHC class I 
expression to nCD35 further increased the AUROC 0.93 and had an optimal sensitivity of 
91% and specificity of 92%.
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SOLUBLE DIAGNOSTIC BIOMARKERS 
C-reactive protein and procalcitonin
C-reactive protein (CRP), an acute phase protein belonging to the pentraxin family, is 
synthesized by the liver and its production is mainly driven by interleukin (IL)-6. It binds to 
phosphocholine, which is present in many prokaryotes, but also in damaged, necrotic and 
apoptotic eukaryotic cells [25]. Concentrations of CRP start to rise 12 to 18h after the onset 
of the systemic inflammatory symptoms [26]. Procalcitonin (PCT) is the pre-hormone of 
calcitonin, produced by the C cells of the thyroid, with a time of induction of several hours, 
but its immunological function is largely unknown [26].
The influence of major types of microorganisms on both markers has been primarily studied 
in community-acquired lower respiratory tract infections (LRTI). Bacterial LRTI are associated 
with higher concentrations of CRP and PCT than viral infections [27-29]. However, studies 
assessing the value of these biomarkers for individual prediction of etiology are scarce. 
In studies using different definitions of LRTI and including patients with different severity, 
AUROC was 0.77 for PCT [30] and varied between 0.76 and 0.84 [27, 30, 31] for CRP, showing 
significant overlap in the lower range of PCT and CRP concentrations. In studies including 
patients with a diverse range of infections, CRP had an AUROC varying between 0.81 and 
0.90, with both sensitivity and specificity ranging from approximately 70% to 80% [10, 32]. 
PCT was assessed in one of these two studies: the AUROC was 0.72 with a sensitivity of 69% 
and a specificity of 51% [32]. Ruling out secondary bacterial infections complicating H1N1 
influenza may be facilitated by the use of PCT, as shown by the sensitivity ranging from 74-
100% (pooled sensitivity 84%) with a negative likelihood ratio of 0.26 in a meta-analysis of 
6 studies [33]. However, it should be acknowledged that currently used methods (the gold 
standard) for detecting secondary bacterial infection probably underdiagnose the disease, 
thereby affecting the evaluation of biomarkers. Specificity was low and varied between 53% 
and 70% (pooled specificity, 64%).
Several studies have reported increased median concentrations of CRP and PCT in patients 
with typical pneumonia compared to patients with atypical pneumonia [28, 29, 34]. Those 
studies, however, did not report test characteristics for the comparison between these two 
groups, but the distribution of the individual values shows considerable overlap, precluding 
individual prediction. In a South-Korean study, CRP and PCT were lower in TB pneumonia 
compared to patients with non-tuberculous LRTIs. The AUROC for distinguishing these 
two groups were 0.86 for CRP and 0.87 for PCT. Tuberculosis could be excluded (negative 
predictive value, 100%), with a cutoff  higher than 1.0 ng/mL for PCT or >150 mg/L for CRP 
[35]. Similar studies found an AUROC of 0.87 and 0.72 for PCT and 0.82 and 0.64 for CRP 
for diagnosing pulmonary tuberculosis as cause of community-acquired pneumonia (CAP) 
[36, 37].
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PCT is the only marker which that has been rigorously studied for management of 
individual patients with suspected infection. A multicenter, randomized controlled trial in 
EDs demonstrated the safety of PCT guiding the initiation and continuation of antibiotic 
treatment in LRTI, compared to standard care [38]. Moreover, antibiotic prescription rate 
decreased from 88% to 75%, and mean antibiotic exposure from 8.7 to 5.7 days, accompanied 
by a reduction of adverse events. Although the PCT cutoff-values used (antibiotic treatment 
strongly discouraged if PCT <0.1 ng/mL; discouraged if PCT 0.10-0.25 ng/mL; encouraged 
if PCT 0.25-0.5 ng/mL; strongly encouraged if PCT >0.5 ng/mL) not necessarily reflect a 
pathogen-specific host response (i.e., low PCT corresponding with a viral infection) and 
could also indirectly mirror the severity and thereby the likelihood of a self-limiting course of 
the infectious episode, this study shows the success of incorporation of host inflammatory 
markers into daily patient care.
Recently, PCT has been proposed as a discriminating marker between invasive fungal 
infections (IFI), mainly invasive candidiasis, and bacterial infections, with lower circulating 
concentrations found in IFI. In a subgroup analysis of their meta-analysis, Dou et al. found 
a pooled AUROC of 0.9, (sensitivity 83%, specificity 78%) of PCT to differentiate between 
IFI and bacterial infections in adults [39]. The populations included in these three studies 
[40-42] and a more recent one [43] differed, but all represented patients at increased risk 
for IFI (prolonged ICU stay, hematological stem cell transplant recipients, neutropenia, or 
major abdominal surgery). A limitation is the small sample size of all studies assessed (44 
IFI patients at most). Nevertheless, PCT concentrations were significantly lower in the IFI 
groups compared to the bacterial infection groups, and cutoff values for ruling in (low PCT 
concentrations) or ruling out (high PCT concentrations) could be defined. Two [42, 43] of 
three studies [40] studying CRP in addition to PCT reported lower concentrations of both 
CRP and PCT in the early phase of IFI than in systemic bacterial infections, and one study 
[43] found an added value of the combination of both markers: AUROC varied between 0.84 
and 0.94. 
A recent systematic review and meta-analysis of studies evaluating PCT for diagnosis of sepsis 
in critically ill patients with SIRS, comprising 30 studies with a total of 3244 patients (90% 
adults), found a summary AUROC of 0.85 and a pooled sensitivity of 77% and specificity of 
79%, suggesting that PCT may be helpful as indicator of sepsis, although it is insufficient as 
stand-alone test [44]. Statistical analysis showed publication bias, and the methodological 
quality of the studies was assessed as moderate. 
CRP has predominantly been included in the studies as comparator for new biomarkers of 
interest to discriminate sepsis from SIRS. Similar to the pattern observed in viral-bacterial 
discrimination, an increase of CRP to some level may be observed both in noninfectious 
SIRS and sepsis, limiting the specificity of low concentrations. However, higher values are 
more specific (100mg/L: 90%), than lower levels (30 mg/L: 63%), but lack sensitivity (60% 
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compared to 80%) [45]. In individual studies the AUROC to discriminate infections from NIID 
ranged widely from 0.65 to over 0.90. However, the highest values were observed in case-
control studies and studies including patients with SIRS without the suspicion of an infection, 
rather than in prospective studies in a consecutive series of patients from a clinical relevant 
population [14, 15, 46-49].
Wu et al. performed a systemic review and meta-analysis to determine the diagnostic 
value of PCT and CRP to discriminate infection from disease flare in febrile patients with a 
variety of auto-immune diseases [50]. PCT had better diagnostic accuracy than CRP: AUROC 
of 0.91 versus 0.81. Particularly the pooled specificity of PCT (with cutoff values ranging 
from 0.09-1.4 ng/mL, but mostly at 0.5 ng/mL) was high: 90%, making it a suitable test for 
ruling in bacterial infections (likelihood ratio for a positive test 7.28). Specificity increased to 
95% at cutoff levels >0.5 ng/mL. However, pooled sensitivity was only 75%, hampering the 
possibility to rule out bacterial infections. CRP had a sensitivity of 77% and a specificity of 
56%, both not good enough for ruling in or out bacterial infections.
Markers of macrophage activation: neopterin and soluble CD163 
Neopterin, a pteridine derived from guanosine triphosphate, is constitutively present 
in low concentrations in serum. Under the influence of IFN-γ the synthesis of neopterin 
by activated monocytes and macrophages increases [51] and, among others, modulates 
macrophage-mediated effector mechanisms [52]. As such, neopterin reflects activated 
cellular immunity. Indeed, two studies from the same center have shown neopterin 
concentrations to be two-fold higher during viral RTI than in (mainly extracellular) bacterial 
RTI [30, 31]. The corresponding AUROC were 0.76 and 0.83, and increased to 0.84 and 
0.86, respectively, when neopterin was combined with CRP. However, ruling out bacterial 
infections was difficult. Furthermore, healthy controls were included in the bacterial group, 
leading to an overestimation of the diagnostic accuracy in one study [30]. Another study, 
among 69 returning travelers with dengue, (para)thypoid fever or Rickettsia africae, showed 
opposite results: neopterin was higher in case of a bacterial origin, probably because of 
the intracellular nature of these infections. The AUROC was 0.67 [53]. For the distinction 
between the presence and absence of an infection in ICU patients developing fever, 
neopterin had an AUROC of 0.73. Gram-positive and Gram-negative infections displayed 
similar neopterin concentrations [47]. 
CD163 is the hemoglobin scavenger receptor on monocytes and macrophages. Its 
extracellular domain, soluble CD163 (sCD163), is constitutively released into the circulation 
[54]. No specific function of this soluble receptor has been defined yet, but the significant 
induction of sCD163 by a wide range of inflammatory signals implies a role in inflammation 
[55]. Studies assessing the diagnostic accuracy are limited. A recent small study showed 
ICU patients with severe sepsis/septic shock (mainly pneumonia) to be accurately 
distinguished from non-infectious SIRS patients matched for disease severity on basis of 
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sCD163 concentrations: the AUROC was 0.95 [46]. However, the control group consisted 
mainly of patients with SIRS due to trauma or cerebral hemorrhage. Patients with less 
severe infections may not be well detected by circulating sCD163, since only patients with 
severe sepsis have been shown to have elevated levels of sCD163 [45]. In a study among 55 
patients with suspected meningitis, sCD163 had a moderate ability to discriminate between 
bacterial infection and non-bacterial disease (e.g. viral infection, malignancy and NIID): 
AUROC 0.72, sensitivity 47%, specificity 91% [56].
Cytokines 
Based on the high concentrations reported in HIV, dengue, Epstein-Barr virus, 
cytomegalovirus and measles infections [57-61], and the role in Th-1 cell differentiation and 
NK-cell stimulation [62], IL-18 has been proposed as a viral biomarker. However, contrary to 
previous reports, respiratory viruses elicit a similar IL-18 response as bacterial pathogens 
[27]. Therefore, in the context of LRTI, the use of IL-18 has limited value in predicting the 
etiology of infection. The use of other cytokines in the distinction between viral and bacterial 
pathogens is also limited. Circulating IL-6 does not perform better than CRP in septic patients 
with LRTI [27]. In a cohort of patients admitted with fever, subsequently diagnosed with 
divergent bacterial and viral infections, IL-6 had an AUROC of 0.83 compared to 0.95 of PCT 
[11]. Circulating IFN-γ did not discriminate between the two groups (AUROC 0.58), and IL-8, 
IL-10 and TNF-α were undetectable (<20 pg/mL) in most patients. Nevertheless, another 
study including patients with influenza-like illness at the ED, mean IL-10 concentrations 
were on average twice as high in the influenza groups compared to those in the bacterial 
groups and other viral infections, but an AUROC was not calculated [63]. Furthermore, IFN-γ 
was undetectable in patients with bacterial pneumonia, leading to an AUROC for IFN-γ of 
0.94 for the distinction between bacterial and viral infection. It has to be said, however, that 
bacterial infection was not culture proven, but clinically and radiographically suspected.
The value of cytokines to discriminate between infection and NIID has been studied in ED 
and ICU populations. In 78 severely ill patients with SIRS and suspected infection, circulating 
IL-6 and IL-8 had modest discriminative value with an AUROC of 0.75 and 0.71, respectively, 
when compared to PCT (AUROC 0.92). IL-6 had a sensitivity of 67% and a specificity of 72%, 
IL-8 a sensitivity of 63% and specificity of 78% [64]. Among 33 ICU patients, Balci et al. found 
an AUROC of 0.52 for IL-6, 0.66 for IL-8, 0.64 for IL-2 and 0.97 for PCT, for the discrimination 
between sepsis and non-infectious SIRS [65]. At the ED, including patients with suspected 
infection, IL-6 (AUROC 0.76) was similar in diagnostic accuracy as PCT (0.74) and CRP (0.79), 
for the differentiation between bacterial infection (mostly septic patients) and non-bacterial 
infection (50% SIRS, many with suspected viral infection) [66]. Also in two other cohorts of 
moderately severe ill patients at the ED, IL-6 did not have a larger AUROC than that of CRP 
and PCT to distinguish between sepsis and non-infectious SIRS [48, 49].
8Chapter 8
115
Other soluble receptors: sTREM-1 and serum decoy receptor 3
The triggering receptor expressed on myeloid cells (TREM) amplifies TLR-induced pro-
inflammatory signals. A soluble form, sTREM-1 is released from activated neutrophils 
and monocytes and has been suggested to be a marker of bacterial and fungal infection 
[67]. In a study among patients presenting with suspected infection, sTREM-1 was higher 
in patients with a LRTI of bacterial origin than in LRTI of viral origin, although there was 
considerable overlap and a diagnostic concentration (>600 pg/mL) of sTREM-1 was only 
present in 10% of patients with bacterial infection [27]. As a surrogate marker for the need 
for antibiotics in admitted patients with CAP, exacerbation of chronic obstructive pulmonary 
disease (COPD) or asthma, sTREM-1 had an AUROC of 0.77 (sensitivity 81%, specificity 65%), 
when the presence of chest infiltrate or an Anthonisen type 1 exacerbation of COPD were 
used as reference standard. Porfyridis et al. compared sTREM-1 concentrations in patients 
with a CAP, clinically or microbiologically diagnosed, to those with a non-infectious etiology. 
The AUROC was 0.77 (specificity 83%, specificity 63%) [68].
 It has also been proposed that sTREM-1 might be of value in discriminating between typical 
and atypical CAP. Twenty-one patients with radiographically-confirmed CAP, mainly caused 
by Streptococcus pneumonia or Haemophilus influenzae, had higher circulating levels of 
sTREM-1 than 14 patients with atypical CAP (Mycoplasma pneumoniae, Legionella species 
or Chlamydophila pneumoniae) (AUROC 0.87, sensitivity 81%, specificity 79%) [69].
A meta-analysis including 1076 sepsis patients and 647 non-infectious SIRS patients from 11 
studies assessed the value of sTREM-1 in the early diagnosis of sepsis at the ED or ICU [70]. 
The chosen cutoff point varied widely from 40 pg/mL to 755 pg/mL. With a pooled sensitivity 
of 79%, a specificity of 80% and an AUROC of 0.87, sTREM-1 had a moderate diagnostic 
accuracy as a single marker. The assay method (ELISA versus Luminex) and sample size were 
important sources of heterogeneity, with smaller studies tending to overestimate the effect 
size. Studies that enrolled trauma patients showed higher diagnostic accuracy than studies 
that included also other types of SIRS patients. Furthermore, statistical analysis indicated 
potential publication bias.
DcR3, a soluble decoy receptor of the TNF receptor family, has been studied primarily in 
cancer. However, two recent small studies investigated DcR3 as infectious biomarker. In 
recently admitted ICU patients comparing (mainly abdominal) sepsis with non-infectious 
SIRS, DcR3 had an AUROC of 0.90, with a sensitivity of 96% and a specificity of 67% [71]. 
Unfortunately, the authors did not describe the way patients were recruited, gave no clinical 
information on the control groups, and did not compare the performance of DcR3 with 
currently used biomarkers. A second study also reported a favorable performance of DcR3 
in separating bacteremic sepsis from non-infectious SIRS on the first two days after ICU 
admission (AUROC 0.96). However, this study did not report the origin of non-infectious 
SIRS and disease severity. Furthermore, a control biomarker was not included [72].
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Soluble TLR receptors, LBP, and CD14
Pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), are germ line-
encoded receptors, that form the basis for discrimination between self and non-self. By 
integrating the signals elicited by pathogen-associated molecular patterns (PAMPs), 
PRRs orchestrate the innate and adaptive immune responses to eliminate the specific 
pathogen. The major cell wall component of Gram-negative bacteria, lipopolysaccharide 
(LPS), interacts with the help of CD14, with the TLR4-MD2-complex, after association with 
LPS-binding protein (LBP) and CD14.. These pathways have been studied mainly for the 
purpose of diagnosing bacterial infections. Indeed, in community-acquired LRTI, circulating 
LBP was significantly higher in patients with a bacterial than a viral cause [27], although 
with an inferior diagnostic accuracy than CRP. A larger study among 240 CAP patients at 
the ED also indicated suggested an association between LPB concentrations and microbial 
etiology. However, pneumonia due to atypical bacterial organisms was associated the 
lowest LBP concentrations: 72% had a concentration below the chosen cutoff level of 14 
µg/mL, compared to 29% of those with typical bacterial pathogens and 25% of those with 
viral pneumonia [34]. Zobel et al. also found lower concentrations of LBP during atypical 
bacterial pneumonia compared to pneumonia caused by typical pathogens, but the overlap 
between the two groups was large [73]. Blairon et al. showed that Gram-negative, Gram-
positive and fungal sepsis elicit similar LBP responses [74].
LPB is not helpful to guide the initiation of antibiotic treatment in patients recently admitted: 
the AUROC was 0.68 and at a concentration of 26 ug/mL LBP failed to identify 10% of the 
patients with an indication for antibiotic treatment (sensitivity 90%), while that cutoff 
would lead it lead to overtreatment in 70% of the patients with viral or self-limited bacterial 
diseases (specificity 29%) [75]. Other studies support the notion that LBP has insufficient 
diagnostic capacity to distinguish infections from non-infectious SIRS (AUROC 0.74–0.63) 
[76, 77]. 
Only one study has evaluated the diagnostic performance of sCD14 in viral and bacterial 
infections. Forty-five patients with clinically or microbiologically diagnosed bacterial 
infections had higher serum concentrations of sCD14 than patients with viral infections 
upon admission, but there was a significant overlap, yielding an AUROC of 0.73 [11]. Other 
studies have focused on the prediction of sepsis on admission and determined the serum/
plasma concentration of a 13kDa fragment of sCD14, named sCD14-subtype (sCD14-ST) or 
presepsin [78-81]. Diagnostic accuracy varied with reported AUROC between 0.70-0.91. The 
wide variation in performance is likely due to the inclusion of controls without suspected 
infection, such as trauma patients or patients with stroke, in some to the studies.
Recently, soluble forms of TLR2 and TLR4 (sTLR2/4) has been described. These proteins 
exert inhibitory activity on TLR signaling [82]. A single case-control study has examined the 
diagnostic capacity of sTLR2 and sTLR4 in a broad range of inflammatory diseases [83]. This 
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proof-of principle study showed circulating sTLR2 and sTLR4 to be higher in patients with 
infection than in patients with NIID. The AUROC for sTLR4 (0.72) was similar to that of CRP 
(0.74), while sTLR2 had an AUROC of 0.60. At a specificity of 95%, sTLRs had a low sensitivity 
(sTLR2, 32%; sTLR4, 16%) to identify an infectious process. For the distinction between viral 
and bacterial infections, sTLR4 had an AUROC of 0.75 and sTLR2 of 0.58, suggesting that 
there is no direct relationship between sTLR shedding and stimulation of TLR2 and 4 by their 
prototypical bacterial ligands. 
sTLR2 and sTLR4 did not differ between patients with bacterial and fungal sepsis [84]. Based 
on its function as receptor of β-1,2 mannoside, a cell wall component of Candida albicans, 
galectin-3 was tested as fungal biomaker [85]. However, circulating galectin-3 concentrations 
proved to be in the same range for bacterial and fungal sepsis [85]. Galectin-3 had an AUROC 
of 0.73 (sensitivity 43%) diagnose infectious disease, and CRP 0.80 for CRP (sensitivity 27%). 
Another recently identified soluble PRR is soluble macrophage-related mannose receptor 
(sMMR) [86]. The extracellular domains of the MMR are cleaved by a metalloproteinase, a 
process that has been shown to take place through fungal beta-glucan recognition but is not 
induced by Staphylococcus aureus [87]. Although these findings seem promising for a the 
qualification of sMMR as a fungal biomarker, a recent small study in the ICU found sMMR 
concentrations to be elevated in patients with non-infectious SIRS (trauma and intracranial 
hemorrhage) and as well as bacterial sepsis [46].
The most useful biomarkers for the main research questions are summarized in Table 1.
Table 1. Most useful biomarkers for the main research questions.
1. Distinction infectious versus non-infectious diseases References
Infection versus disease flare in patients with inflammatory diseases PCT 50
SIRS versus sepsis nCD64, DcR3 20, 21/71, 72
2. Viral versus bacterial infection
Bacterial super infection in influenza PCT 33
LRTI PCT 38
Undifferentiated illness nCD35 10
3. Bacterial versus fungal infection
High-risk population PCT (±CRP) 40-43
4. Specific infectious agent
None
COMBINATION OF BIOMARKERS
Most pattern recognition pathways and effector mechanisms are involved in the immune 
response against various types of microorganisms, and a precise etiologic diagnosis remains 
a challenge with single marker analysis. Moreover, biomarker expression is dependent on 
the interval between onset of the infectious insult and presentation, and may reflect severity 
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rather than a pathogen-specific response. Combining biomarkers may offer a solution to 
this problem. Indeed, this strategy has been shown to improve the diagnostic value of single 
markers in some [21, 30, 32], although not all studies [27, 88]. Most biomarkers examined 
are stimulated both by bacterial and viral pathogens, but reach higher concentrations 
during bacterial infection. Therefore, moderately increased levels of these biomarkers 
can be found during both bacterial and viral infections, limiting the sensitivity. Neopterin 
has been proposed to be a ‘viral’ biomarker, since intracellular infections lead to elevated 
concentrations. Combination with CRP (a ‘bacterial’ biomarker) has been shown to increase 
the AUROC compared to CRP alone in respiratory tract infections [30, 31]. Although the 
increase in overall diagnostic accuracy is usually moderate, significant gain can be achieved 
in ruling in (increase in specificity) or out (increase in sensitivity) a certain condition for a part 
of the patients. Multiple regression analysis showed the performance of the combination 
of nCD64 with PCT and sTREM-1 to be better than that of each biomarker taken individually 
for the diagnosis of sepsis in critically ill ICU patients [21]. Sepsis could be excluded in 96% of 
the patients with all three markers below an established threshold, while sepsis was present 
in 96% of the patients with two of the three markers elevated.
Genome-wide transcriptional studies of circulating leukocytes simultaneously measure 
the expression of a large number of genes and provide an integrated view of the immune 
response. Using microarray technology and advanced statistical analytical tools, gene 
expression profiling is an emerging technology for immune response-based diagnosis 
of inflammatory and infectious diseases [89]. A multicenter prospective trial showed a 
transcriptomic profile of 42 markers to have an AUROC of 0.92 to differentiate community-
acquired sepsis from surgery-induced SIRS. Simplification of the model to 7 genetic markers 
yielded an accuracy of 0.86 [90]. The potential usefulness of gene expression profiling 
beyond separating sepsis from non-infectious SIRS comes from a study in Thailand among 
63 bacteremic patients, in which a gene profile of 37 genes was able to distinguish between 
melioidosis and sepsis due to other microorganisms with 100% accuracy (true positive + 
true negative/all tests) in the discovery cohort and around 80% in the two validation 
cohorts [91]. Another study, however, demonstrated a 138-gene profile of peripheral blood 
mononuclear to represent a non-specific, more general inflammatory response [92]. The 
value of transcriptome analysis in viral infections has been shown by Zaas et al. [93]: using 
three human experimental viral infection cohorts (rhinovirus, influenza A and respiratory 
syncytial virus) an acute respiratory viral signature consisting of mRNA expression of 30 
genes was derived, which correctly identified 97% (accuracy) of the individuals with a viral 
infection. In an independent validation cohort, this signature distinguished 100% of children 
with influenza A infection from healthy controls. More importantly, influenza infection or 
pneumococcal pneumonia could be correctly separated in 93% (31/33) [93]. 
These studies confirm that different pathogens elicit distinct immune responses and suggest 
the value of obtaining a signature of the host immune response by gene expression profiling 
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in differential diagnosis. Nevertheless, large prospective studies are needed to validate these 
findings and to assess the impact on clinical decision making. Furthermore, standardization 
in techniques and data analysis are crucial before this technique can be brought into clinical 
practice.
CONCLUSIONS AND FUTURE PERSPECTIVES
Both infectious and non-infectious insults evoke an inflammatory response. Individual 
components of the host response are used as biomarkers in daily practice, such as WBC, CRP, 
and PCT, and many more markers are being studied. However, single biomarker analysis 
seems to be insufficient as a stand-alone test for an etiologic diagnosis, although promising 
biomarkers exist and PCT has been shown to be of value in decision making (Table 1). The 
usefulness of a combination of biomarkers as signature of the host immune response is 
supported by studies exploring gene expression profiling of peripheral blood leukocytes. 
In this review we focused on inflammatory biomarkers as etiologic predictors, without 
addressing advances in rapid microbiological tests. The combination of these two classes 
of markers may be an attractive strategy for a rapid diagnosis. The identification of new 
markers may be based on pathophysiological concepts, as has been employed in most 
current studies, but proteome-wide analysis may lead to discovery of novel biomarkers 
[94]. Reports of such new markers should adhere to the STARD criteria in order to optimize 
accuracy and completeness of the data and to facilitate qualitative evaluation by readers 
[95]. The value of these data should be ultimately evaluated in diagnostic randomized 
clinical trials.
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SUMMARY
Laboratory diagnostic tests, as adjunctive to clinical symptoms and signs, are indispensable 
in the care for febrile patients. Distinction between an infectious or non-infectious origin 
of inflammation and the etiologic prediction of an infectious insult has important clinical 
consequences. On the one hand, a delay in administration of adequate antimicrobial therapy 
is associated with increased morbidity and mortality [1, 2]. On the other hand, excessive 
antibiotic use should be prevented because of increasing bacterial and fungal resistance, 
potential adverse events and increased costs [3]. In this thesis, the identification of new 
(combinations of) diagnostic biomarkers based on host immune response to infection was 
examined. Furthermore, we aimed to evaluate the diagnostic value of cytokine production 
assays for the characterization of patients with suspected immunodeficiencies.
In recent years measles infection continued to be responsible for over 100.000 deaths 
worldwide, mostly children in developing countries [4]. Failure to vaccinate is responsible 
for ongoing outbreaks, placing mostly children at risk for severe complications like 
dehydration and pneumonia, as witnessed also by the present study in a population of 
unvaccinated Roma children from the Cluj county in North-West of Romania (Chapter 2). 
Pneumonia and oral thrush affected nearly two-thirds and half of the measles patients, 
respectively. Characterization of the acute inflammatory response showed that, besides the 
absence of leukocytosis, measles infection also lacked other classical features of the acute-
phase response, such as markedly elevated plasma concentrations of C-reactive protein 
(CRP), interleukin (IL)-6 or IL-1Ra. Instead, increased concentrations of IL-18 and interferon 
(IFN)-γ appeared to be a hallmark of the acute inflammatory profile in measles, which is 
in line with the T-helper-1  response that is essential for viral clearance [5]. Furthermore, 
lymphocytopenia and strikingly elevated lactate dehydrogenase (LDH) concentrations were 
found. The combination of these findings differed significantly from a control group of 
febrile children with an exanthematous febrile illness of other origins, suggesting that this 
inflammatory signature can be used in differential diagnosis of fever and rash in children.
In Chapter 3, we followed up on the combination of plasma biomarkers in a study including 
septic patients with lower respiratory tract infections (LRTI) visiting the emergency 
department because of a suspected infection. We compared CRP alone with five combinations 
of CRP with one additional inflammatory biomarker [lipopolysaccharide binding protein 
(LBP), procalcitonin (PCT), IL-6, IL-18, or soluble triggering receptor expressed on myeloid 
cells-1 (sTREM-1)] for the discrimination between a bacterial and viral etiology. CRP had an 
area under the receiver operating characteristics curve (AUROC) of 0.82 (95% CI 0.70–0.93), 
indicating moderate diagnostic accuracy. Despite the previous suggestions of IL-18 being 
a ‘viral’ biomarker, IL-18 concentrations did not differ between the two groups [6-9]. The 
combination of CRP with any of the other makers had no significant effect on the AUROC 
compared to CRP alone. In the subgroup including only patients with CRP >150 mg/L (highly 
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specific for bacterial LRTI), addition of another marker to CRP did not improve the diagnostic 
accuracy either.
Based on the hypothesis that soluble Toll-like receptor (sTLR)2 and 4 are differentially 
released during various inflammatory diseases, we studied the release of sTLR2 and 
sTLR4 both in peripheral blood mononuclear cell (PBMC) cell culture experiments, in-
vivo during experimental human endotoxemia, and in plasma of patients with infectious 
and noninfectious inflammatory disorders (NIID) (Chapter 4). TLRs are germline-encoded 
receptors that recognize mostly bacterial and fungal components of the cell wall, either 
alone or in combination with co-receptors [10]. The recognition of a few viral components 
has been described, but that takes place mostly intracellular at the level of the endosomes. 
Soluble forms of TLR2 and TLR4 have been described to be released in biological fluids [11, 
12] but to date have not been studied as serologic biomarkers. In-vitro, the TLR4 ligand E. 
coli-derived LPS, the TLR2 ligand Pam3Cys, and heat-killed E. coli all induced the release 
of sTLR2 and sTLR4, indicating that shedding of the TLRs is not confined to stimulation of 
its corresponding cell surface receptor. Similarly, LPS administration to healthy volunteers 
resulted in a distinct and reproducible pattern of both circulating sTLR2 and sTLR4 with 
peaks after 4 hours and 2 hours, respectively. sTLR4 did not correlate with circulating 
cytokine concentrations, but sTLR2 had a positive correlation with TNF-α and IL-6 and 
tended to correlate positively with IL-1Ra and negatively with IL-10, respectively. In the light 
of the anti-inflammatory properties of these soluble receptors [13], and of the differentially 
regulated release of sTLRs compared to IL-1Ra and IL-10, it is suggested that these proteins 
are potential complementary strategies to reduce inflammation. The diagnostic accuracy 
of sTLR4 is similar to CRP regarding the discrimination between infectious and NIID, while 
sTLR2 is inferior to CRP in this respect. CRP surpassed both the diagnostic capacity of sTLR2 
and sTLR4 for identification of a viral or bacterial infection. Combination of two biomarkers 
(CRP with one of the soluble TLRs) did not improve the diagnostic accuracy.
In Chapter 5, we further explored the role of pattern-recognition receptors (PRR) as 
diagnostic biomarkers. Galectin-3 functions, among others, as a PRR for the fungal cell wall 
component β-1,2 mannoside [14]. Despite of this however, we demonstrated that plasma 
galectin-3 concentrations were not differentially regulated during candidemia and bacterial 
sepsis. Galectin-3 did, however, discriminate between patients with infectious diseases 
(viral LRTI, bacterial sepsis, candidemia) and patients with NIID (gout, autoinflammatory 
syndrome, pancreatitis). Furthermore this study suggested that the sequential use of CRP 
and galectin-3 may be superior to CRP alone for the distinction of infections from NIID.
In Chapter 6 we explored a different category of host-derived biomarkers: volatile 
compounds in exhaled breath. We focused on nitric oxide (NO), a small molecule whose 
production by the inducible isoform of NO synthase (iNOS) is tremendously increased under 
inflammatory conditions [15]. In septic shock, NO plays a key role in the pathophysiology 
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of vascular dysfunction [16]. In a study including mechanically ventilated septic patients 
with or without pneumonia and a control group consisting of patients after cardiac surgery 
or major acute cerebral pathology, we showed that local production, rather than systemic 
clearance, is responsible for the increased concentrations of exhaled NO during pneumonia. 
Furthermore, we found a time-dependent decline in exhaled NO during septic shock and 
the presence of pneumonia was associated with increased concentrations of exhaled 
NO. However, significant overlap was found between those with respiratory sepsis and 
non-respiratory sepsis, probably due to the complex balance between production and 
consumption of NO [17]. Thus, on individual level, exhaled NO cannot be used to diagnose 
pneumonia. 
In Chapter 7 we demonstrated that one-third of adults with severe, recurrent or 
opportunistic infections or unexplained NIID have deficient production of the lymphocyte-
derived cytokines IFN-γ, IL-17A and/or IL-22. These defects support the notion that many 
more patients than previously thought suffer from a narrow, specific immune deficiency 
[18]. These functional assays were helpful in the diagnosis, and for identifying the ultimate 
cause of some immunodeficiencies, such as detecting STAT1 mutations in autosomal 
dominant chronic mucocutaneous syndrome and STAT3 mutations in hyper IgE syndrome 
patients. Consistent with their immunological properties, defective IFN-γ production was 
primarily found in patients with recurrent or severe mycobacterial or fungal infections, 
while defective IL-17A and IL-22 deficiency was associated mainly with mucocutaneous 
fungal infections. A quarter of the patients with NIID had IFN-γ deficiency, possibly reflecting 
IL-17 overproduction as has been proposed to be central in the pathogenesis of hidradenitis 
suppurativa [19]. The importance of the functional assessment of immune function is 
apparent through the possibility to guide immunomodulatory therapy such IL-1Ra (to block 
overinflammation) or recombinant IFN-γ (for specific defects). Interestingly, monocyte-
derived cytokine production was only rarely affected.
GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES
In this thesis, we investigated diagnostic strategies for rapid identification of infectious 
pathology, and we assessed the value of functional tests to detect underlying defective 
cytokine production. As such, we have tried to contribute to a personalized approach of 
patients with inflammatory disorders: rapid identification of patients who need antimicrobial 
therapy, those who will benefit from immunomodulatory therapy, and selection of those in 
whom expensive microbiological investigations and potential toxic antibiotic therapy can be 
safely omitted.
In the studies presented here, we show that sTLR2 and sTLR4 are suitable circulating 
biomarkers reaching different concentration in divergent inflammatory conditions. In 
addition to sTLR2 and sTLR4, it can be concluded that another soluble PRR, galectin-3, 
9Chapter 9
131
is useful as circulating biomarker. However, the diagnostic accuracy of these markers as 
stand-alone test is insufficient to guide clinical decisions. The complexity of inflammatory 
responses on infectious and non-infectious insults and the overlap in involved pathways 
argues for combination of biomarkers as diagnostic tool. Indeed, the combination of CRP 
and galectin-3, in a sequential fashion, seems to be better than CRP alone in identifying an 
infection. In suspected viral infection with rash, the combination of elevated concentrations 
of LDH and IL-18 and lymphocytopenia in the context of low or moderately elevated 
acute-phase reactants points towards measles infection. Nevertheless, the combination of 
CRP with LBP, PCT, IL-6, IL-18, or sTREM-1 is not superior to CRP alone for discrimination 
between viral and bacterial origin of LRTI. Furthermore, cytokine-production assays are 
promising tools to detect deficient production of IFN-γ, IL-17A of IL-22 cytokine production 
in patients with severe, recurrent or opportunistic infections and may guide genetic testing 
and immunotherapy.
Clinical practice would benefit from biomarkers with higher sensitivity and specificity. 
However, given the long quest for the ‘perfect’ biomarker and the frequent failure to validate 
promising ones, this remains challenging. Unbiased proteomics instead of hypothesis-based 
specific biomarker determination may offer a successful strategy in homogeneous patient 
populations [20]. Besides circulating markers, the use of volatile organic compounds (VOC) 
in breath, either as single marker or as a fingerprint, show promising results for the diagnosis 
of bacterial and fungal pulmonary infection [21]. A complete signature of the host immune 
response, as aimed with the combination of (circulating) biomarkers, may be obtained 
through gene expression profiling of peripheral blood leukocytes. Specific viral and bacterial 
signatures have been found [22] by this upcoming strategy and further differentiation of the 
causative agent into species level may even be possible [23]. Furthermore, although alone 
they contain insufficient diagnostic information, incorporation of certain symptoms and 
signs into prediction models should be encouraged [24]. With regard to immunodeficiencies, 
the implications of cytokine-production assays for patient management needs further 
assessment. 
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Chapter 10
NEDERLANDSE SAMENVATTING
Naast anamnese en lichamelijk onderzoek is laboratoriumdiagnostiek onmisbaar in de 
zorg voor patiënten met koorts. Het maken van een onderscheid tussen een infectieuze 
en niet-infectieuze ontsteking en het vaststellen van de oorzaak van deze ontsteking heeft 
belangrijke klinische consequenties. Het tijdig toedienen van de juiste antimicrobiële 
therapie voorkomt morbiditeit en mortaliteit [1, 2], echter overmatig antibioticagebruik 
dient vermeden te worden vanwege het gevaar op resistentieontwikkeling van bacteriën 
en schimmels en de hiermee geassocieerde potentiële bijwerkingen en toegenomen 
kosten [3]. In dit proefschrift onderzochten wij nieuwe (combinaties van) diagnostische 
biomarkers gekozen op basis van een verwachte afweerrespons. Daarnaast hadden we tot 
doel de diagnostische waarde van cytokineproductietesten te onderzoeken bij patiënten die 
geanalyseerd werden in verband met een mogelijke afweerstoornis.  
In de afgelopen jaren overleden meer dan 100.000 mensen, met name kinderen in 
ontwikkelingslanden, aan mazelen [4]. Uitbraken zijn het gevolg van gebrek aan vaccinatie, 
waardoor vooral kinderen een risico lopen op complicaties zoals uitdroging en longontsteking. 
Wij beschrijven een uitbraak onder ongevaccineerde Roma kinderen in de regio Cluj in het 
noordwesten van Roemenië (Hoofdstuk 2). Twee derde ontwikkelde een longontsteking en 
de helft kreeg een orale Candida-infectie. De acute ontstekingsreactie werd gekenmerkt 
door de afwezigheid van een leukocytose en andere kenmerken van de acutefaserespons, 
zoals duidelijk verhoogde concentraties van het C-reactieve eiwit (CRP), interleukine (IL)-6 
en IL-1Ra. Typerend waren de verhoogde concentraties van IL-18 en interferon (IFN)-γ in de 
acute fase. Dit weerspiegelt de Thelper -1-reactie die nodig is voor de klaring van het virus 
[5]. Daarnaast vonden we een lymfocytopenie en aanzienlijk verhoogde concentraties van 
lactaatdehydrogenase (LDH). De combinatie van deze bevindingen verschilde significant van 
een controlegroep bestaande uit kinderen met koorts en huiduitslag, maar zonder mazelen. 
Dit suggereert dat dit biomarkerprofiel gebruikt kan worden in de differentiële diagnostiek 
van koorts en huiduitslag bij kinderen.
In Hoofdstuk 3, keken we eveneens naar het nut van het combineren van biomarkers, 
ditmaal in een studie met septische patiënten met een lageluchtweginfectie, die de 
spoedeisende hulp bezochten vanwege het vermoeden van een infectie. We vergeleken 
het onderscheidend vermogen van CRP alleen en met vijf combinaties van CRP met één 
andere inflammatoire biomarkers [lipopolysaccharide-bindend eiwit (LBP), procalcitonine, 
IL-6, IL-18 of sTREM-1]. Het oppervlak onder de ‘receiver operator characteristic’ curve 
(AUROC) van CRP was 0.82 (95%-betrouwbaarheidsinterval 0.70-0.93), passend bij een 
matig onderscheidend vermogen. Ondanks de eerdere suggesties dat IL-18 kan fungeren 
als een ‘virale’ biomarker, verschilde IL-18 niet tussen de twee groepen [6-9]. De combinatie 
van CRP met één van de andere biomarkers had geen significant effect op de AUROC in 
vergelijking met CRP alleen. In de subgroep van patiënten met een CRP-waarde >150 mg/L 
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(zeer specifiek voor een bacteriële infectie), gaf de toevoeging van een biomarker aan CRP 
evenmin een verbetering van het onderscheidend vermogen ten opzichte van CRP alleen.
Gebaseerd op de hypothese dat ‘soluble Toll-like receptor’ (sTLR)2 en sTLR4 in verschillende 
mate vrijkomen gedurende verschillende inflammatoire ziekten, bestudeerden wij het 
vrijkomen van sTLR2 en sTLR4 zowel in gekweekte mononucleaire cellen uit het perifere 
bloed (PBMC), als in-vivo gedurende experimentele humane endotoxinemie en in 
plasma van patiënten met infectieuze en niet-infectieuze inflammatoire aandoeningen 
(Hoofdstuk 4). TLRs zijn receptoren die vooral bacteriële en schimmelcomponenten van 
de celwand herkennen, soms samen met co-receptoren [10]. De herkenning van enkele 
virale bestanddelen zijn beschreven, maar dat vindt vooral intracellulair plaats. Oplosbare 
vormen van TLR2 en TLR4 worden uitgescheiden in biologische vloeistoffen [11, 12], maar 
tot nu toe zijn deze nog niet onderzocht als serologische biomarkers. In-vitro, induceren LPS 
afkomstig van E. coli (een TLR4 ligand) en Pam3Cys (een TLR2 ligand) beide het vrijkomen 
van sTLR2 and sTLR4. Dit toont aan dat het afsplitsen van TLRs niet voorbehouden is aan 
stimulatie van de corresponderende celgebonden receptor. Intraveneuze toediening van 
LPS aan gezonde vrijwilligers leidde eveneens tot zowel circulerend sTLR2 als sTLR4, met 
een piek op respectievelijk 4 en 2 uur. sTLR4 correleerde niet met cytokineconcentraties, 
maar sTLR2 correleerde positief met TNF-α en IL-6 concentraties en neigde tot een positieve 
correlatie met IL-1Ra en een negatieve correlatie met IL-10. Gezien de anti-inflammatoire 
eigenschappen van deze oplosbare receptoren zouden deze eiwitten, naast de anti-
inflammatoire cytokines IL-1Ra en IL-10, mogelijk een complementaire manier zijn om 
inflammatie te verminderen [13]. Wat betreft het maken van onderscheid tussen infectieuze 
en niet-infectieuze inflammatie, is sTLR4 even goed als CRP, maar presteert sTLR2 minder 
dan CRP. CRP was beter dan sTLR2 en sTLR4 wat betreft het discrimineren tussen een 
virale of bacteriële infectie. Combinaties van biomarkers verbeterden het onderscheidend 
vermogen niet.
In Hoofdstuk 5 onderzochten we de rol van een andere patroonherkennende receptor (PRR) 
als diagnostische biomarker. Galectine-3 is een PRR dat onder andere β-1,2 mannoside 
herkent, een  celwandbestanddeel van schimmels [14]. Desalniettemin vonden we gelijke 
concentraties van galectine-3 in het plasma tijdens een schimmelinfectie (candidemie) en 
bacteriële sepsis. Galectine-3 onderscheidde echter wel patiënten met infecties (virale lage 
luchtweginfecties, bacteriële sepsis en candidemie) van patiënten zonder infecties (jicht, 
autoinflammatoire syndromen en pancreatitis). Daarnaast suggereert deze studie dat het 
sequentiële gebruik van CRP en galectin-3 voor het maken van dit onderscheid mogelijk 
beter is dan CRP als enkelvoudige biomarker.  
In Hoofdstuk 6 onderzochten we een andere categorie biomarkers: vluchtige stoffen in 
de uitademingslucht. We concentreerden ons op stikstofoxide (NO), een klein molecuul, 
waarvan de productie aanzienlijk toeneemt tijdens inflammatie [15]. Tijdens septische 
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shock speelt NO een sleutelrol in de pathofysiologie van vasculaire dysfunctie [16]. In een 
studie met beademde septische patiënten met of zonder pneumonie en een controlegroep 
van patiënten na cardiale chirurgie of grote acute cerebrale pathologie, toonden we aan dat 
lokale productie, in plaats van systemische klaring, verantwoordelijk is voor de toegenomen 
concentraties van uitgeademde NO tijdens een pneumonie. Daarnaast vonden we een 
tijdsafhankelijke afname van uitgeademde NO. Er was echter wel een overlap tussen 
patiënten met en zonder pneumonie, waarschijnlijk ten gevolge van de complexe balans 
tussen productie en consumptie van NO [17]. Dus op individueel niveau kan NO in de 
uitademingslucht niet gebruikt worden om een pneumonie vast te stellen. 
In Hoofdstuk 7 toonden we aan dat een derde van de volwassenen met ernstige, 
terugkerende of opportunistische infecties of onverklaarde niet-infectieuze inflammatoire 
aandoeningen een gebrekkige productie heeft van de door lymfocyten geproduceerde 
cytokines IFN-γ, IL-17A en/of IL-22. Deze gevonden deficiënties ondersteunen de recente 
opvatting dat veel meer patiënten lijden aan een afweerstoornis dan voorheen werd 
aangenomen [18]. Deze functionele bevindingen bleken behulpzaam bij het vaststellen van 
een mutatie in STAT1 bij autosomaal dominante mucocutane candidiasis en de diagnose van 
het hyper IgE syndroom bij verscheidene patiënten. Overeenkomstig hun immunologische 
eigenschappen, werd een verminderde productie van IFN-γ overwegend gevonden bij 
patiënten met een mycobacteriële of schimmelinfectie en was een verminderde IL-17A en 
IL-22 respons geassocieerd met mucocutane schimmelinfecties. Een kwart van de patiënten 
met een niet-infectieuze inflammatoire aandoening (met name hidradenitis suppurativa) 
had een IFN-γ deficiëntie. Het is mogelijk dat dit een overproductie van IL-17 weerspiegelt 
[19]. De uitkomsten van deze testen zouden het gebruik van immunotherapie, in de zin 
van recombinant IFN-γ (voor specifieke defecten) of IL-1Ra (om overstimulatie van IL-17 te 
blokkeren), kunnen sturen. Opvallend was dat de productie van de cytokines geproduceerd 
door monocyten slechts zelden was aangedaan. 
CONCLUSIE EN TOEKOMST
In dit proefschrift onderzochten we nieuwe diagnostische strategieën voor de snelle 
identificatie van infectieuze pathologie en de waarde van functionele testen om een 
onderliggende verminderde cytokineproductie op te sporen. Daarmee hebben we geprobeerd 
om een bijdrage te leveren aan de ontwikkeling van een gepersonaliseerde benadering 
van patiënten met ontstekingsziekten: snelle identificatie van patiënten die antimicrobiële 
therapie nodig hebben, identificatie van hen die mogelijk immuunmodulerende therapie 
kunnen gebruiken en selectie van diegenen waarbij duur microbiologisch onderzoek en 
potentieel toxische antibiotische therapie veilig achterweg gelaten kan worden.
In de alhier gepresenteerde studies tonen we aan dat sTLR2 en sTLR4 geschikte circulerende 
biomarkers zijn die verschillende concentraties bereiken tijdens uiteenlopende inflammatoire 
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aandoeningen. Naast sTLR2 en sTLR4, concluderen we dat galactine-3 gebruikt kan worden 
als circulerende biomarker. Het onderscheidend vermogen van deze drie markers is echter 
ontoereikend om op grond daarvan klinische beslissingen te nemen. De immunologische 
respons op infectieuze en niet-infectieuze prikkels is complex en maken voor een deel gebruik 
van dezelfde mechanismen. Dit pleit voor combinaties van biomarkers als diagnostisch 
hulpmiddel. De combinatie van CRP en galectine-3 lijkt inderdaad beter dan CRP alleen voor 
het vaststellen van een infectie. Bij kinderen met huiduitslag en het vermoeden van een 
virale infectie, wijst de combinatie van een gestegen concentratie van LDH en IL-18 en een 
lymfocytopenie in de aanwezigheid van niet of matig verhoogde acutefase-eiwitten in de 
richting van mazelen. Desalniettemin is de combinatie van CRP met LBP, PCT, IL-6, IL-18, of 
sTREM-1 niet beter dan CRP alleen voor het maken van een onderscheid tussen een virale 
of bacteriële oorzaak van een lage luchtweginfectie. Daarnaast zijn cytokineproductietesten 
veelbelovend voor het opsporen van een onderliggend tekort aan IFN-γ, IL-17A of IL-22 bij 
patiënten met ernstige, recidiverende of opportunistische infecties en kunnen deze testen 
genetische diagnostiek en immunotherapie sturen. 
De patiëntenzorg is gebaat bij biomarkers met een hoge sensitiviteit en specificiteit. Echter, 
de reeds lange zoektocht naar de ‘perfecte’ biomarker en het veelvuldig falen van de 
validatie van veelbelovende markers, laten zien dat de ontdekking van zulke biomarkers 
een grote uitdaging zal zijn. Ongeselecteerde bestudering van alle eiwitten in plaats van 
een hypothese gedreven bepaling kan een succesvolle strategie zijn in een specifieke 
patiëntenpopulatie [20]. Naast circulerende markers, zijn er hoopvolle resultaten van het 
gebruik van vluchtige organische stoffen in de uitademingslucht, als enkelvoudige marker of 
als profiel, voor de diagnose van een pneumonie veroorzaakt door een bacterie of schimmel 
[21]. Het verkrijgen van een volledige signatuur van de afweerreactie, zoals bedoeld met 
het combineren van (circulerende) biomarkers, kan verkregen worden door te kijken naar 
het genexpressieprofiel van leukocyten in het perifere bloed. Specifieke virale en bacteriële 
patronen zijn gevonden door middel van deze nieuwe techniek [22] en verdere specificatie 
van de verwekker tot op speciesniveau lijkt mogelijk [23]. Klinische symptomen en 
bevindingen bij het lichamelijk onderzoek leiden vaak niet direct tot een diagnose, maar het 
incorporeren van deze gegevens in predictiemodellen tezamen met andere diagnostische 
testen zoals de beschreven biomarkers in dit proefschrift kan zeker toegevoegde waarde 
hebben voor het snel en accuraat stellen van een diagnose en derhalve dient deze strategie te 
worden aangemoedigd [24]. Met betrekking tot immuundeficiënties, dienen de implicaties 
van cytokineproductietesten voor het beleid nader te worden onderzocht. 
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